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A B S T R A C T
The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a
hallmark of many forms of cancer. Identifying the epigenetic mechanisms that govern these changes and de-
veloping therapeutic approaches to modulate them, is a well-established avenue pursued in translational cancer
medicine. Chronic myeloid leukemia (CML) arises clonally when a hematopoietic stem cell (HSC) acquires the
capacity to produce the constitutively active tyrosine kinase BCR-ABL1 fusion protein which drives tumor de-
velopment. Treatment with tyrosine kinase inhibitors (TKI) that target BCR-ABL1 has been transformative in
CML management but it does not lead to cure in the vast majority of patients. Thus novel therapeutic approaches
are required and these must target changes to biological pathways that are aberrant in CML − including those
that occur when epigenetic mechanisms are altered. These changes may be due to alterations in DNA or histones,
their biochemical modifications and requisite ‘writer’ proteins, or to dysregulation of various types of non-coding
RNAs that collectively function as modulators of transcriptional control and DNA integrity. Here, we review the
evidence for subverted epigenetic mechanisms in CML and how these impact on a diverse set of biological
pathways, on disease progression, prognosis and drug resistance. We will also discuss recent progress towards
developing epigenetic therapies that show promise to improve CML patient care and may lead to improved cure
rates.
1. Introduction
Chronic myeloid leukemia (CML) arises when the t9;22 transloca-
tion (the Philadelphia chromosome) [1,2] occurs in a hematopoietic
stem cell (HSC), resulting in constitutive expression of the fusion tyr-
osine kinase BCR-ABL1 [3], and transformation of the HSC into a leu-
kemic stem cell (LSC). The clonal myeloproliferative neoplasm that
follows is driven by BCR-ABL1 expression and subversion of normal
signalling pathways. CML is rare with an annual incidence of ≈1–2
cases per 100,000 individuals and a peak incidence in the sixth to se-
venth decade of life [4]. The vast majority (85–90%) of patients present
in chronic phase (CP) and then, if untreated, progress to advanced
phase (AP) and blast phase (BP) within five years [5] resembling an
acute leukemia with poor prognosis. The development of potent tyr-
osine kinase inhibitors (TKI), such as imatinib, which target BCR-ABL1
is arguably the best example of a targeted cancer therapy. TKI were
introduced into the clinic almost two decades ago and have transformed
the management of CML [6,7]. However, they have not cured CML for
the vast majority of patients as only 10–20% of them can discontinue
therapy and achieve long-term treatment-free remission (TFR) [8–10].
More recent evidence suggests that the proportion achieving TFR will
increase, with as many as 46% of patients on longer term therapy
(> 8 years) or 2nd generation TKI (2G-TKI) qualifying for TKI dis-
continuation [11], with half of these likely to achieve TFR [12]. A
quarter of patients will fail TKI therapy [13], most often due to the
acquisition of BCR-ABL1 kinase domain or other mutations [14,15] and
in a minority of cases as a result of progression to AP/BP [16]. For the
remaining ≈50–60% of patients on life-long TKI, minimal residual
disease is maintained by a sub-population of LSC[17] in the bone
marrow (referred to as LSC persistence) [18–21] which are TKI-re-
sistant [22–24] and can serve as a reservoir for disease relapse if TKI
therapy is discontinued. Thus, in order to improve cure rates for CML,
there is still a significant clinical need to develop novel therapeutic
approaches that target LSCs and are effective for patients who fail TKI
therapy. Many of the pathways subverted by BCR-ABL1 have been
studied intensively as a means of identifying dysregulated components
that can be selectively targeted to eradicate the disease when used in
combination with, or as an alternative to, TKI (reviewed in detail in
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[16]).
It is now widely acknowledged that cancers are, in part, epigen-
etically-driven diseases, where epigenetic dysregulation acts in concert
with genetic abnormalities to provide an environment to facilitate
tumor formation, maintenance and progression. Indeed, in a stem cell
disease such as CML, the consequences of such dysregulation may have
heightened importance as epigenetic processes are known to be critical
for stem cell maintenance and development [25–27]. Epigenetic pro-
cesses are typically defined within three broad categories: histones and
histone modifications, DNA methylation, and non-coding RNAs. Col-
lectively, these can exert their effects to (i) directly regulate tran-
scription, DNA damage/repair and DNA replication, (ii) regulate RNA
levels and stability post-transcriptionally, and (iii) regulate protein
translation or post-translational protein modifications (Fig. 1). Muta-
tions in components of these pathways are relatively rare in CP CML
(Table 1), pointing to epigenetic dysregulation via other ways. Such
mutations are detected, however, at higher frequency during disease
progression and the proportions of leukemic cells which carry mutation
(s) can change in response to TKI therapy. For the purposes of this re-
view we will present examples of how each of these three categories of
epigenetic processes is dysregulated in CML, how they impact on
critical pathways, and how they may provide new therapeutic oppor-
tunities to overcome the current clinical bottlenecks and improve cure
rates for CML.
2. Histone modifiers and modifications
Biochemical post-translational modifications of histone tails within
nucleosomes of chromatin [28], such as methylation or acetylation, can
alter chromatin condensation and topology or provide sites of recruit-
ment for other factors. Such modifications or marks are regulated by
‘writer’ proteins with opposing enzymatic activities; for example, his-
tone acetyl- or methyl- transferases (HATs and HMTs) or histone dea-
cetylase or demethylases (HDACs and HDMs) that can add or remove
modifications, respectively, at specific amino acid residues. Further
levels of complexity are contributed by histone variants [29] and the
ability of ‘writer’ proteins to target the post-translational modification
of non-histone proteins (Fig. 1). In CML, a number of these histone
marking systems are dysregulated, the consequences of which affect
numerous pathways that leukemic cells utilise for survival (Table 2).
Fig. 1. Layers of epigenetic regulation in CML. Expression of BCR-ABL1 subverts a number of signalling pathways (examples shown) which contribute to, or result from, epigenetic
dysregulation in CML cells. The schematic diagram illustrates the three classes of epigenetic processes that have been widely studied and regulate transcription and DNA damage/repair in
CML (DNA methylation, histone modifications and non-coding RNAs). Nucleosomes are composed of 2 molecules of histones H2B, H2A, H3 and H4 and are shown here for simplicity as
spheres around which the DNA double helix is entwined. Protein-coding or non-coding genes are shown as the coloured rectangles between nucleosomes. DNA methylation is shown at
CpG sequences and the process of demethylation is represented by the addition of eOH. HATs = histone acetyltransferases. HDACs = histone deacetylases. HMTs = histone methyl-
transferases. HDMs = histone demethylases. DNMTs = DNA methyltransferases. TETs = Ten-eleven translocation enzymes. lncRNA = long non-coding RNA. ROS = reactive oxygen
species which contributes to DNA damage. All other symbols are described in the legend at the bottom of the schematic.
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2.1. DNA damage, H2AX and histone acetylation
Histone variant H2AX is incorporated into chromatin at varying
frequencies [30] and is a known tumor suppressor − haplo-in-
sufficiency of which can facilitate progression to BP in a CP-CML
murine model [31]. It is widely known that the phosphorylated form of
H2AX, known as γ-H2AX, found at sites of DNA damage in chromatin, is
a critical mediator in the cellular decisions that lead to DNA repair or
apoptosis [32,33]. Several lines of evidence point to dysregulation of
this response in CML. Higher basal levels of γ-H2AX are found in CML
cells compared to normal [34,35], consistent with the findings that cells
expressing BCR-ABL1 show enhanced levels of oxidative DNA damage,
including point mutations and double-stranded breaks (DSBs) induced
by endogenous reactive oxygen species (ROS) [36,37]. Inducing addi-
tional DSBs in CML and non-CML CD34+ cells results in further in-
creases in γ-H2AX that persist longer in CML. Earlier reports in cell line
models suggested the CML response was of a short duration − in
keeping with a more rapid response to DNA damage [38] via the error-
prone DNA repair mechanisms known to be active in CML cells
[39–41]. CML cells also show increased levels of H3 and H4 acetylation
which co-localizes with γ-H2AX at sites of DNA damage [34]. These
acetylation changes are likely to reflect a more generalised increase in
histone H3 and H4 acetylation and HAT activity and a reduced HDAC
activity in CML − all of which are dependent on BCR-ABL1 kinase
activity [34,42]. Altering the balance of HAT/HDAC activity in CML
cells may also lead to increased TP53 acetylation at residues that can
block the translocation of TP53 from the nucleus to the cytoplasm and
prevent mitochondrial-dependent apoptosis in response to DNA damage
[43]. One possible mechanism for this imbalance in acetylation/dea-
cetylation is the ability of BCR-ABL1 to sequester HDAC1 in the cyto-
plasm [42], which has the additional effect of promoting expression of
BCR-ABL1 through increased nuclear H4 acetylation in a positive
feedback loop (Fig. 2a).
2.2. SUV39H1 loss of function and lysine methylation
Histone H3 lysine 9 trimethylation (H3K9me3) is a hallmark of
heterochromatin with the methyltransferases SETDB1, SUV39H1 and
SUV39H2 responsible for its deposition. However, it also plays roles in
the cell-type repression of lineage-inappropriate genes during devel-
opment [44] and is dysregulated across cancer types [45,46]. CP CML
CD34+ cells and granulocytes show significantly reduced levels of
Table 1
DNA mutations/SNPs in epigenetic regulators or miRNA targets. Column one: Gene name. Column two: encoded protein and function (if known). Column three: epigenetic class. Column
four: the type (in italics) and frequency of DNA changes are shown as actual number of cases (i) in CP/AP/BP CML or (ii) in TKI-responder, resistant or progressed patients [183]. Column
five: clinical significance as described in the cited reference(s). Column six: cited reference(s). Abbreviations: CP = chronic phase; AP = advanced phase; BP = blast phase.
Gene Protein/Function Epigenetic class Type/Frequency Clinical significance Reference
DNMT3A DNA methyltransferase DNA methylation mutation pre-leukaemic lesion; CP-CML;
TKI treatment
[183,184]
3 of 29 CP
2 of 74 TKI
responders
IDH1 isocitrate dehydrogenase mutation BP-CML [15,185–188]
4 of 194 BP
IDH2 isocitrate dehydrogenase mutation BP-CML [15,185–188]
5 of 194 BP
TET2 methylcytosine dioxygenase 2 mutation CP-CML; AP-CML; BP-CML; TKI
treatment
[15,183–187,189,190]
3 of 138 CP
2 of 14 AP
9 of 79 BP
2 of 74 TKI
responders
3 of 18 TKI resistant
1 of 8 progressed
TET3 methylcytosine dioxygenase 3 mutation CP-CML [189,190]
1 of 24 CP
MSH6 G/T Mismatch-Binding Protein DNA repair/
replication
mutation CP-CML [189,190]
1 of 24 CP
ASXL1 Polycomb Repressive Complex 2; H3K27 methylation histone modification mutation CP-CML; BP-CML; TKI
treatment
[15,183–187,189–191]
12 of 139 CP
12 of 80 BP
3 of 74 TKI
responders
3 of 18 TKI resistant
2 of 8 progressed
EZH2 Polycomb Repressive Complex 2; histone
methyltransferase; H3K27 methylation
mutation CP-CML [15,184]
1 of 29 CP
KDM1A HMT activity; H3K4 and H3K9 methylation mutation CP-CML [189,190]
1 of 24 CP
KMT2A MLL1; HMT activity; H3K4 methylation mutation CP-CML; TKI treatment [183]
1 of 74 TKI
responders
KMT2D MLL2; HMT activity; H3K4 methylation mutation CP-CML; TKI treatment [183]
1 of 74 TKI
responders
2 of 18 TKI resistant
ARHGAP26 RhoGTPase; target of miR-18a-3p miRNA SNP 3' UTR increased risk of CP-CML [192]
rs187729 T > C
30 of 140 CP
IRF8 interferon regulatory factor 8; target of miR-330-3p SNP 3' UTR increased risk of CP-CML [192]
rs10514611 C > T
84 of 140 CP
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H3K9me3 [47,48] compared to normal, although appreciable levels of
both H3K9me2 and H3K9me1 (associated with less repressive chro-
matin states) are evident in granulocytes [48]. Mechanistically, re-
ductions of H3K9me3 levels in CP CML CD34+ cells are linked to cy-
toplasmic co-localisation of SUV39H1 by BCR-ABL1 and support a
model whereby normal nuclear activity of SUV39H1 [47] and also
HDAC1 [42] (see section above) are subverted. This would create a
more permissive transcriptional chromatin environment and facilitate
expression of genes normally repressed by the SUV39H1/HDAC1
complex [49]. Later work has shown the opposing effects of H3K9me3
and histone H3 serine 10 phosphorylation (H3S10p) in CML cells. In-
hibition of the kinase activities of either BCR-ABL1 or the ‘writer’
protein Aurora kinase B (AURK) results in loss of H3S10p and increases
H3K9me3 levels, thus repressing BCR-ABL1 expression [50]. Collec-
tively these results are compatible with the model proposed in Fig. 2a.
2.3. PRMT5 and arginine methylation in LSC survival
Histone arginine methylation, laid down by the PRMT family of
HMTs, can activate or repress transcription depending on the histone
residues and the dimethyl isomers (a = asymmetrical or s = symme-
trical) involved [51]. Early work on one family member, PRMT5,
showed it to interact strongly with the V617F mutant form of JAK2
found in BCR-ABL1-negative myeloproliferative neoplasm [52]. Later,
PRMT5 was shown to be a critical regulator in neuronal stem cell
renewal [53] and, more recently, in CML LSC survival [54]. PRMT5 is
upregulated by STAT5 in CML CD34+ cells where it is associated with
increased histone arginine methylation compared to normal CD34+
cells. Genetic or pharmacological inhibition of PRMT5 enzymatic ac-
tivity in CML CD34+ cells diminished this methylation and significantly
reduced LSC numbers in vitro and reduced long-term engraftment po-
tential in murine xenografts. The critical role for PRMT5 in CML is
thought to be centred on the epigenetic regulation of canonical Wnt
signalling− a pathway known to be essential for LSC function [55,56]
(Fig. 2b). In LSC, elevated PRMT5 activity triggers up-regulation of
DVL3, an upstream positive regulator of β-catenin, as a consequence of
elevated H3 arginine 2 dimethylation (H3R2me2) at the DVL3 pro-
moter. Intriguingly, elevated PRMT5 activity also leads to down-reg-
ulation of the microRNA (miRNA; miR) miR-203, a negative regulator
of BCR-ABL1, through H3 arginine 8 and H4 arginine 3 dimethylation
(H3R8me2s and H4R3me2 s respectively) at the miR-203 promoter.
Reduction of miR-203 creates a scenario where BCR-ABL1 and down-
stream PRMT5 expression are reinforced in a positive feedback loop.
2.4. The polycomb group proteins
The polycomb group proteins found in either polycomb repressive
complex 1 (PRC1) or complex 2 (PRC2) are arguably some of the best
characterised ‘writer’ complexes and function as potent repressors of
gene expression [57,58]. Components of these complexes are de-
Fig. 2. Dysregulation of histone methylation in CML. A. Lower levels of histone H3 lysine 9 trimethylation are found in CML cells and this is linked to the direct interaction of BCR-ABL1
with SUV39H1 (and also HDAC1) in the cytoplasm. This creates transcriptionally permissive chromatin associated with H3 serine 10 phosphorylation (H3S10p) and H4 acetylation at
target genes, including BCR-ABL1, in the nucleus− thus allowing their expression [47,48,50]. B. A positive feedback loop between BCR-ABL1 and the methyltransferase PRMT5 results in
increased levels of histone H3 arginine 2 symmetric demethylation which in turn activates Wnt signalling and its transcriptional targets [54]. C. In CML, re-programming of Polycomb
Repressive Complex 2 and its methyltransferase subunit EZH2 alters the balance between pro- and anti-apoptotic responses via altered dependencies on histone H3 lysine 27 tri-
methylation [61–64,67]. This may also involve a positive feedback loop involving BCR-ABL1 which reinforces EZH2 expression via MYC (public ENCODE datasets) and STAT [62]. Gene
transcription is denoted by the blue text in italics. Steps in pathways/processes that are active in CML cells are shown with solid lines; steps that are blocked in CML are shown with dotted
lines. All other symbols are as described in Fig. 1. MK–0457 = Aurora kinase inhibitor; IM = imatinib. s = symmetrical histone arginine methylation.
S. Koschmieder, D. Vetrie Seminars in Cancer Biology 51 (2018) 180–197
184
regulated across many cancer types where they can act as either tumor
suppressors or oncogenes [59,60]. PRC2 is a multi-protein complex that
contains either the HMT EZH1 or EZH2 and lays down histone H3 ly-
sine 27 mono-, di- and tri-methylation. The trimethylated form
(H3K27me3) is a hallmark of PRC2-EZH2 repressive activity. Several
studies have demonstrated dysregulation of PRC2 in CML primary pa-
tient material, cell lines or murine models [61–64] and their expression
levels may be altered in response to TKI [64,65] or progression to BP
disease [66]. Two recent studies have demonstrated the important role
of EZH2 in LSC survival. Loss of EZH2 HMT function in either a murine
model of CML, or in CP patient samples examined in vitro or in murine
xenografts, significantly impairs LSC survival [63,64]. In human LSC,
this was shown to be due to an increased dependency of pro-apoptotic
genes on PRC2-EZH2 repression which is not evident in HSC (Fig. 2c).
Others have shown that EZH2 dysregulation (controlled by BCR-ABL1
via MYC and STAT5) may have other consequences in CML cells. EZH2
associates with β-arrestin to drive H4 lysine acetylation and BCR-ABL1
expression [61], or with PRAME to repress the function of the death
receptor TNFSF10 [67]. The microRNA miR-219 is down-regulated
through the action of EZH2 and DNA methylation at its promoter; this
facilitates the up-regulation of XIAP, an anti-apoptotic factor and
known miR-219 target. Whether all of these events occur in LSC is not
known but provides the basis for further studies.
The PRC1 complex works co-operatively with PRC2 and presence of
both PRC2 and PRC1 leads to chromatin compaction and transcrip-
tional silencing of target genes [57]. PRC1 binds to H3K27me3 in
chromatin, and lays down histone H2A lysine 119 ubiquitinylation,
through the action of its catalytic components − the E3-ligases RING1
or RING2. The stem cell factor BMI1 (also known as PCGF4) is a core
component of PRC1 activity and emerging evidence supports it having
an important role in cancer. In CP-CML, levels of BMI1 are elevated in
total mononuclear and CD34+ cells compared to normal [68,69].
Several pathways known to be important in CML cell survival have
been shown to be the targets of PRC1-BMI1 activity. In one study, BMI1
was shown to repress the expression of ZMYM3 in CML, a component of
HDAC complexes [69] (Fig. 3a). ZMYM3 repression was linked to up-
regulation of the oncogene FOS via histone H3 acetylation − thus ac-
tivating a pathway recently shown to be critical for TKI-resistant LSC
and progenitor survival [70]. BMI1 was also shown to directly down-
regulate CCNG2 in CML cells − a regulator of the tumor suppressor
PP2A, a known modulator of Wnt signalling [71,72]. Up-regulating C-
CNG2 was able to dissociate PP2A subunits and drive an autophagic
response in CML cells via PKCζ and ERK/JNK signalling [73] (Fig. 3a).
The role of autophagy in CML LSC is well documented [74–76] and
BMI1 inhibition could sensitize CML cells to autophagy inhibitors.
2.5. Epigenetic ‘writers’ and non-histone targets
Repression of apoptosis is a central survival mechanism and uni-
fying theme across cancer types. Therefore it follows that inactivation
of TP53 itself is one of the few non-histone targets of epigenetic ‘writer’
activity in CML that has thus far been identified. Inactivation of TP53
can be achieved through acetylation by HATs (see also above) or
through deacetylation by HDACs such as SIRT1, a NAD-dependent
deacetylase [77]. SIRT1 expression is up-regulated in CP-CML CD34+
cells and is further elevated during disease progression [78,79]. The
dysregulation of SIRT1 expression in CML is likely to be epigenetically-
driven by aberrant DNA methylation (Fig. 3b) and is discussed further
below. Inhibition of SIRT1 has been shown to significantly increase
TP53 acetylation, resulting in up-regulation of the apoptotic response
and a reduction of LSC and progenitor cell survival in vitro and in
murine models [79]. One unexpected and additional function of SIRT1
in CML is that it promotes the acquisition of genetic mutations by
deacetylating components of the DNA repair machinery and increasing
error-prone DNA repair [80]. Thus, the duality of SIRT1 function in
CML allows DNA damage to be accumulated, whilst suppresses cell
death − making SIRT1 an interesting player in the DNA damage re-
sponse via its non-histone activities.
3. DNA methylation
DNA methylation represses gene transcription and occurs at cyto-
sine residues in CpG dinucleotides where it is laid down by DNA methyl
transferases (DNMTs) and removed passively through cell division or
actively by methyl-cytosine dioxygenases (also known as ten-eleven
translocation proteins; TETs) [81]. CpG methylation occurs throughout
genomes [82,83], however, it is at promoter regions in CpG islands
[84–86] that its effects on transcriptional repression are normally ex-
erted. Cancer genomes have been shown to exhibit widespread global
hypomethylation in addition to more targeted gains or loss of DNA
methylation at tumor suppressors or oncogenes [87,88]. Spanning more
than twenty years of CML research, candidate gene approaches have
been instrumental in identifying changes in DNA methylation at spe-
cific genes (Table 3).
3.1. DNA methylation and CML survival pathways
Three examples of epigenetically-dysregulated genes in CML, in
particular, highlight the impact that dysregulating DNA methylation
may have on CML survival pathways. Firstly, the upregulation of SIRT1
in CML (see also above) can most easily be explained by hypermethy-
lation of the HIC1 gene − a repressor that functions in concert with
SIRT1 [89] to auto-regulate SIRT1 expression (Fig. 3b). The promoter of
HIC1 is hypermethylated in CP, and this increases during disease pro-
gression [90] and coincides with upregulation of SIRT1 [78]. Thus,
reduction of HIC1 expression would facilitate the up-regulation of
SIRT1 via STAT5 [78]. However, whilst this mechanism has been
proposed [79], it has not been empirically tested. Secondly, the tumor
suppressor MTSS1 is down-regulated in LSC and progenitor cells of CML
mouse models and CP patients at diagnosis, but is restored to normal
levels during TKI therapy [91]. MTSS1 down-regulation is linked to
higher DNA methylation levels at its promoter in CML compared to
normal and is accompanied by the recruitment of the transcription
factor ZBTB33 (KAISO) and the potent repressor REST1 [92,93]
(Fig. 3c). MTSS1 is a known target of DNMT3B [94], and both me-
thylation and DNMT3B levels have an inverse relationship with MTSS1
expression in naïve and TKI-treated cells. Repression of MTSS1 is likely
to promote CML LSC and progenitor cell proliferation and motility, both
of which can be reduced upon MTSS1 enforced expression [91].
Treatment with the de-methylating agent 5-azacytidine in vitro was able
to strongly induce MTSS1 in CML cell lines. Finally, the CD70/CD27
axis has been shown to activate non-canonical Wnt signalling in the
presence of TKI, thus contributing to LSC survival [95]. This is due to
the opposing effects that TKI has on expression of DNMT1A and SP1 via
the suppression microRNA miR-29 (Fig. 3d). Lowering miR-29 expres-
sion allows SP1 levels to increase, whilst reducing DNMT1A. This re-
sults in loss of DNA methylation at the CD70 promoter and CD70 ac-
tivation by SP1 which can then drive Wnt signalling and β-catenin
stabilization. CD70 knockdown synergized with TKI treatment to
eliminate LSC in both xenograft and retroviral mouse models [95].
4. Non-coding RNAs
Non-coding RNAs are a more recently emerging epigenetic process
that can regulate mRNA levels and protein translation through a variety
of somewhat related processes (Fig. 1). Anti-sense transcripts are long
non-coding RNAs (lncRNAs) that are transcribed from the strand op-
posite to that of the sense transcript; for this reason, they can result in
transcriptional interference with the sense transcript by a variety of
mechanisms [96,97]. miRNAs are small or short non-coding RNAs of
≈20–23 nucleotides, that are processed from longer precursor RNAs.
They regulate gene expression through sequence-specific binding most
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often to the 3′ untranslated regions of target mRNAs and either prevent
translation or induce cleavage of the mRNA [98]. miRNAs may also
compete for target mRNAs, according to the competitive endogenous
RNA (ceRNA) hypothesis [99–101]. Of these various processes, the
roles of miRNAs, in particular, are well established in cancer biology
[102,103]. While there are relatively few reports of lncRNAs or ceRNAs
being dysregulated in CML cells compared to normal, the number of
dysregulated miRNAs is considerable (Table 4).
4.1. MicroRNAs, the niche and the CXCL12/CXCR4 axis
The impact of dysregulated miRNAs on a number of cellular path-
ways in CML is shown in several of the examples above (Figs. 2b,c, 3d)
and is also reviewed in detail elsewhere [104–111]. One other area of
miRNA biology that is germane to the discussions here is how they
regulate non-cell autonomous pathways via exosomal transfer between
cell types [112–114]. In CML, the expression of the chemokine CXCL12
in the bone marrow microenvironment (BMM) and its receptor CXCR4
expressed on LSC have been demonstrated to play roles in LSC homing
and survival [115–118]. In CML, interactions between leukemic cells
and the bone marrow stroma are defective due to BCR-ABL1 suppres-
sion of CXCR4-mediated signalling (Fig. 3e). This, in turn, reduces
homing capacity and allows primitive CML cells to escape from the
bone marrow [119]. Extrapolation of recent evidence obtained from
CML cell lines in co-culture with endothelial cells [120] suggests that
exosomal transfer of miR-126 from leukemic cells to stromal cells may
also inhibit CXCL12/CXCR4 signalling in vivo through down-regulation
of CXCL12 in the stroma. Levels of miR-126 in exosomal vesicles of
CML cell lines are higher than in the parent cells producing them.
Tracking experiments demonstrated that miR-126 can be transferred
from leukemic to endothelial cells, where it can target the down-reg-
ulation of both CXCL12 and VCAM1, the consequences of which are
reduced cell motility and adhesion between the two cell types. This
would support the view that exosomal ‘shuttles’ may have an important
role in CML-stromal cell interactions in the BMM.
5. Epigenetics in progression and prognosis
In addition to epigenetic processes having roles in subverting cri-
tical cellular pathways in CML, they are also further dysregulated
during disease progression.
5.1. Histone modifiers
Granulocytic H3K9me3 levels increase during AP and BP in concert
with increased levels of the H3K9me3 binding protein, HP1, suggesting
that both features may serve as biomarkers of disease progression [48].
BMI1 increases further during progression from CP to BP [65,66].
Furthermore, BMI1 was shown to be approximately two-fold elevated in
AP- and BP-CML as compared to CP, both in PBMCs and PB CD34+ cells
[121]. In a retrospective cohort of 64 patients with CP CML, above-
median levels of BMI1 mRNA expression in CD34+ cells at diagnosis
Fig. 3. The diversity of epigenetic mechanisms utilised in CML cells. A. BMI1 regulation inhibits the response to autophagy via repression of CCNG2 [73] and permits expression of FOS
[69]− a critical survival factor [70]. B. Up-regulation of SIRT1 through its inability to auto-regulate lead to deacetylation and inactivation of TP53 [78,79,90]. C. The tumor suppressor
MTSS1, which controls cell migration and proliferation, is down-regulated as a result of increased DNA methylation and recruitment of repressive transcription factors to its promoter
[91]. D. TKI up-regulates the Wnt/β-catenin pathway by inhibiting miR-29 expression thus allowing increased CD70 expression and CD70/CD27 receptor/ligand interaction [95]. E. Cell
non-autonomous regulation of the CXCL12/CXCR4 axis may involve the exosomal export of miR-126 to endothelial cells in the microenvironment where it reduces expression of CXCL12,
thus inhibiting signalling via CXCR4 in CML cells [120]. Steps in pathways/processes that are active in CML cells are shown with solid lines; steps that are blocked in CML are shown with
dotted lines. All other symbols are as described in Fig. 1.
S. Koschmieder, D. Vetrie Seminars in Cancer Biology 51 (2018) 180–197
186
Ta
bl
e
3
G
en
es
an
d
ot
he
r
fe
at
ur
es
w
it
h
al
te
re
d
D
N
A
m
et
hy
la
ti
on
in
C
M
L.
C
ol
um
n
on
e:
ge
ne
/f
ea
tu
re
.C
ol
um
n
tw
o:
en
co
de
d
pr
ot
ei
n
an
d
fu
nc
ti
on
(i
fk
no
w
n)
.C
ol
um
n
th
re
e:
st
at
us
w
it
h
re
sp
ec
tt
o
hy
pe
r
or
hy
po
m
et
hy
la
ti
on
in
C
M
L.
C
ol
um
n
fo
ur
:C
M
L
ce
ll
ty
pe
st
ud
ie
d
(p
ri
m
ar
y
pa
ti
en
t
m
at
er
ia
l
or
ce
ll
lin
es
).
C
ol
um
n
fi
ve
:
cl
in
ic
al
si
gn
ifi
ca
nc
e
as
de
sc
ri
be
d
in
th
e
ci
te
d
re
fe
re
nc
e(
s)
.
C
ol
um
n
si
x:
ci
te
d
re
fe
re
nc
e(
s)
.
A
bb
re
vi
at
io
ns
:
PB
=
pe
ri
ph
er
al
bl
oo
d;
BM
=
bo
ne
m
ar
ro
w
;
M
N
C
=
m
on
on
uc
le
ar
ce
lls
;
LS
C
=
le
uk
em
ic
st
em
ce
ll;
C
P
=
ch
ro
ni
c
ph
as
e;
A
P
=
ad
va
nc
ed
ph
as
e;
BP
=
bl
as
t
ph
as
e;
IF
N
=
in
te
rf
er
on
;W
BC
=
w
hi
te
bl
oo
d
co
un
t;
C
C
R
=
co
m
pl
et
e
cy
to
ge
ne
ti
c
re
m
is
si
on
;N
D
=
no
t
de
te
rm
in
ed
.
G
en
e/
R
eg
io
n
Pr
ot
ei
n
fu
nc
ti
on
St
at
us
in
C
M
L
C
M
L
C
el
l
ty
pe
C
lin
ic
al
si
gn
ifi
ca
nc
e
R
ef
er
en
ce
up
to
89
7
ge
ne
s
va
ri
ou
s
hy
pe
r/
hy
po
m
et
hy
la
ti
on
PB
M
N
C
;B
M
M
N
C
di
se
as
e
pr
og
re
ss
io
n
[1
47
]
A
BC
B1
P-
gl
yc
op
ro
te
in
efl
ux
pu
m
p
hy
pe
rm
et
hy
la
ti
on
BM
M
N
C
im
at
in
ib
re
si
st
an
ce
;i
m
at
in
ib
re
sp
on
se
[1
99
]
A
BL
1
(P
h+
ch
ro
m
)
on
co
ge
ne
;t
yr
os
in
e
ki
na
se
PB
M
N
C
;B
M
M
N
C
al
l
C
M
L
st
ag
es
;d
is
ea
se
pr
og
re
ss
io
n;
in
de
pe
nd
en
t
of
BC
R
-A
BL
1
m
R
N
A
le
ve
ls
;
re
sp
on
se
to
IF
N
α
th
er
ap
y;
p2
10
fo
rm
of
BC
R
-A
BL
1
[1
30
,1
33
,1
39
–1
46
]
A
TG
16
L2
au
to
ph
ag
y-
re
la
te
d
pr
ot
ei
n
16
-2
PB
M
N
C
;B
M
M
N
C
C
P-
C
M
L;
BP
-C
M
L;
di
se
as
e
pr
og
re
ss
io
n
[1
48
]
A
TP
5B
m
it
oc
ho
nd
ri
al
A
TP
as
e
K
56
2;
BM
M
N
C
di
se
as
e
pr
og
re
ss
io
n;
ad
ri
am
yc
in
re
si
st
an
ce
[1
61
]
BC
L2
L1
1
Bc
l-2
in
te
ra
ct
in
g
pr
ot
ei
n
Bi
m
BM
M
N
C
im
at
in
ib
re
si
st
an
ce
[1
59
,2
00
]
BC
R
br
ea
kp
oi
nt
cl
us
te
r
re
gi
on
PB
M
N
C
su
rv
iv
al
;i
m
at
in
ib
re
sp
on
se
;i
m
at
in
ib
do
se
;a
ge
[2
01
]
C
A
D
M
1
ce
ll
ad
he
si
on
m
ol
ec
ul
e
1
PB
M
N
C
;B
M
M
N
C
BP
-C
M
L
[1
32
]
C
A
LC
A
ca
lc
it
on
in
;G
-c
ou
pl
ed
re
ce
pt
or
PB
M
N
C
;B
M
M
N
C
di
se
as
e
pr
og
re
ss
io
n
[1
34
–1
36
]
C
BY
1
be
ta
-c
at
en
in
an
ta
go
ni
st
K
56
2;
BM
M
N
C
C
P-
C
M
L
[2
02
]
C
D
70
tu
m
or
ne
cr
os
is
fa
ct
or
lig
an
d
K
BM
5r
C
P-
C
M
L;
TK
I
pe
rs
is
te
nt
LS
C
[9
5]
C
D
H
13
ca
he
ri
n
fa
m
ily
m
em
be
r
PB
M
N
C
;B
M
M
N
C
al
l
C
M
L
st
ag
es
[1
32
,1
33
]
C
D
K
N
2A
ce
ll
cy
cl
e
in
hi
bi
to
r
p1
6
PB
M
N
C
;B
M
M
N
C
A
P-
C
M
L;
BP
-C
M
L;
di
se
as
e
pr
og
re
ss
io
n
[1
25
–1
27
]
ce
ll
cy
cl
e
in
hi
bi
to
r
p1
4
PB
M
N
C
A
P-
C
M
L;
BP
-C
M
L;
di
se
as
e
pr
og
re
ss
io
n
[1
25
,1
28
,1
29
]
C
D
K
N
2B
ce
ll
cy
cl
e
in
hi
bi
to
r
p1
5
PB
M
N
C
;B
M
M
N
C
C
P-
C
M
L;
BP
-C
M
L;
di
se
as
e
pr
og
re
ss
io
n
[1
26
–1
33
]
C
EB
PA
m
ye
lo
id
tr
an
sc
ri
pt
io
n
fa
ct
or
PB
M
N
C
di
se
as
e
pr
og
re
ss
io
n
[2
03
]
C
TS
L
ly
so
so
m
al
cy
st
ei
ne
pr
ot
ei
na
se
PB
M
N
C
di
se
as
e
pr
og
re
ss
io
n
[2
04
]
D
A
PK
1
de
at
h
re
ce
pt
or
1
PB
M
N
C
;B
M
M
N
C
se
x;
di
se
as
e
pr
og
re
ss
io
n;
BP
-C
M
L;
im
at
in
ib
re
si
st
an
ce
[1
26
,1
27
,1
37
,1
38
]
D
D
IT
3
D
N
A
da
m
ag
e
re
sp
on
se
BM
M
N
C
re
du
ce
d
W
BC
[2
05
]
D
LX
4
ho
m
eo
bo
x
pr
ot
ei
n
BM
M
N
C
di
se
as
e
pr
og
re
ss
io
n
[2
06
]
D
PY
S
py
ri
m
id
in
e
m
et
ab
ol
is
m
K
56
2;
PB
M
N
C
hy
pe
rm
et
hy
la
to
r
ph
en
ot
yp
e
[1
33
]
EB
F2
ea
rl
y
B-
ce
ll
fa
ct
or
2;
tr
an
sc
ri
pt
io
n
fa
ct
or
PB
M
N
C
;B
M
M
N
C
C
P-
C
M
L;
BP
-C
M
L;
di
se
as
e
pr
og
re
ss
io
n
[1
48
]
ES
R
1
es
tr
og
en
re
ce
pt
or
1
PB
M
N
C
;B
M
M
N
C
BP
-C
M
L
[1
32
]
FH
IT
ce
ll
cy
cl
e
re
gu
la
to
r
BM
M
N
C
BP
-C
M
L
[1
26
]
H
O
X
A
4
ho
m
eo
bo
x
pr
ot
ei
n
PB
M
N
C
im
at
in
ib
re
si
st
an
ce
[1
60
]
H
IC
1
tr
an
sc
ri
pt
io
na
l
re
pr
es
so
r
PB
M
N
C
;B
M
M
N
C
di
se
as
e
pr
og
re
ss
io
n
[9
0]
IG
F2
in
su
lin
gr
ow
th
fa
ct
or
2
PB
M
N
C
;B
M
M
N
C
lo
ss
of
im
pr
in
ti
ng
du
ri
ng
di
se
as
e
pr
og
re
ss
io
n
[2
07
]
JU
N
B
tr
an
sc
ri
pt
io
n
fa
ct
or
;o
nc
og
en
e
PB
M
N
C
C
P-
C
M
L;
BP
-C
M
L
[2
08
]
M
-B
C
R
m
aj
or
br
ea
kp
oi
nt
cl
us
te
r
re
gi
on
PB
M
N
C
;B
M
M
N
C
Ph
−
an
d
Ph
+
C
P-
C
M
L;
IF
N
re
m
is
si
on
;
di
st
in
gu
is
h
ly
m
ph
oi
d
an
d
m
ye
lo
id
BP
[2
09
–2
11
]
M
G
M
T
D
N
A
re
pa
ir
PB
M
N
C
;B
M
M
N
C
C
P-
C
M
L;
BP
-C
M
L
[1
26
,1
32
]
M
SH
1
m
is
m
at
ch
re
pa
ir
A
TP
as
e
PB
M
N
C
;B
M
M
N
C
C
P-
C
M
L
[1
32
]
M
TS
S1
ac
ti
n
dy
na
m
ic
s
K
56
2;
PB
M
N
C
C
P-
C
M
L
[9
1]
N
PM
2
hi
st
on
e
ch
ap
er
on
e
K
56
2;
PB
M
N
C
al
l
C
M
L
st
ag
es
;i
m
at
in
ib
in
to
le
ra
nc
e/
re
si
st
an
ce
[1
33
]
O
SC
P1
tu
m
or
su
pp
re
ss
or
;
pr
o
ap
op
to
ti
c
K
56
2;
PB
M
N
C
di
se
as
e
pr
og
re
ss
io
n;
su
rv
iv
al
(p
re
-i
m
at
in
ib
);
im
at
in
ib
in
to
le
ra
nc
e/
re
si
st
an
ce
[1
33
]
PA
C
R
G
ch
ap
er
on
in
-b
in
di
ng
pr
ot
ei
n
BV
17
3;
TC
C
-S
;K
U
81
2;
K
Y
O
-1
;
K
56
2;
BM
M
N
C
BP
-C
M
L
(l
ym
ph
oi
d)
[2
12
]
PA
R
K
2
e3
ub
iq
ui
ti
n
lig
as
e
BV
17
3;
TC
C
-S
;K
U
81
2;
K
Y
O
-1
;
K
56
2;
BM
M
N
C
BP
-C
M
L
(l
ym
ph
oi
d)
[2
12
]
PD
LI
M
4
PD
Z
an
d
LI
M
do
m
ai
n
4
pr
ot
ei
n
K
56
2;
PB
M
N
C
su
rv
iv
al
(p
re
-
an
d
po
st
-i
m
at
in
ib
)
[1
33
]
PE
R
2
ci
rc
ad
ia
n
cl
oc
k
ge
ne
PB
M
N
C
C
P-
C
M
L;
BP
-C
M
L
[2
13
]
PE
R
3
ci
rc
ad
ia
n
cl
oc
k
ge
ne
PB
M
N
C
di
se
as
e
pr
og
re
ss
io
n
[2
13
]
PG
R
A
pr
og
es
te
ro
ne
re
ce
pt
or
PB
M
N
C
di
se
as
e
pr
og
re
ss
io
n
[1
33
]
PG
R
B
pr
og
es
te
ro
ne
re
ce
pt
or
PB
M
N
C
di
se
as
e
pr
og
re
ss
io
n
[1
33
]
PL
C
D
1
ph
os
ph
ol
ip
as
e
C
BM
M
N
C
al
l
C
M
L
st
ag
es
[2
14
]
PR
A
M
E
re
pr
es
so
r
of
re
ti
no
ic
ac
id
re
ce
pt
or
BM
M
N
C
di
se
as
e
pr
og
re
ss
io
n
(h
yp
om
et
hy
la
ti
on
)
[2
15
]
PT
PN
6
ty
ro
si
ne
ph
os
ph
at
as
e
PB
M
N
C
;B
M
M
N
C
di
se
as
e
pr
og
re
ss
io
n
[2
16
]
R
A
R
B
re
ti
no
ic
ac
id
re
ce
pt
or
β
BM
M
N
C
BP
-C
M
L
[1
26
]
R
A
SS
F1
A
ce
ll
cy
cl
e;
R
as
si
gn
al
lin
g
K
56
2
N
D
[2
17
]
sF
R
Ps
se
cr
et
ed
fr
iz
zl
ed
re
la
te
d
pr
ot
ei
ns
;
W
nt
si
gn
al
lin
g
BM
M
N
C
im
at
in
ib
re
si
st
an
ce
[2
18
]
(c
on
tin
ue
d
on
ne
xt
pa
ge
)
S. Koschmieder, D. Vetrie Seminars in Cancer Biology 51 (2018) 180–197
187
were associated with significantly inferior survival as compared to
below-median BMI1 levels [121]. Thus, high BMI1 expression was
predictive of poor outcome in patients with CML.
Later work provided a possible explanation for the role of BMI1 in
disease progression. Using the tetracycline-controlled SCLtTA/BCR/
ABL mouse model reflecting CP CML [122], one study showed that
BMI1 was able to reprogram B-lineage progenitor cells during CP CML-
like disease and to turn them into B-cell acute lymphoblastic leukemia
(B-ALL) initiating cells [123]. The B-ALL was serially transplantable.
Overexpression of BMI1 in hematopoietic stem cells (HSCs) or multi-
potent progenitors (MPPs) did not result in B-ALL in vivo, as assessed by
limiting dilution analysis [123]. The presence of continuous BCR-ABL1
was required for the ALL phenotype, since abrogation of BCR-ABL1
expression by doxycycline re-administration rescued the mice from
ALL-mediated lethality [123]. Thus, these data suggest that in patients
with CML, BMI1 may synergize with BCR-ABL1 to induce lymphoid
blast phase by transforming B-lineage progenitors expressing BCR-
ABL1. Immunophenotypic data on the type of blast phase were not
provided in the retrospective expression cohort [121] but a second
functional study showed that BMI1 overexpression in human CD34+
cells from CML patients induced transplantable B-lineage ALL after
transplantation of these cells into NOD/SCID mice [124]. This study
also showed that BMI1 induced BCR-ABL1 positive acute leukemia was
biased towards the lymphoid lineage, supporting the above-mentioned
mouse model [123,124]. The mechanism may involve p16 and p19
(equivalent to human p14) repression and possibly EBF1, PAX5, and
IKZF1 downregulation [123,124].
5.2. DNA methylation
Reports of hypermethylation during disease progression at genes
such as CDKN2A [125–129], CDKN2B [126–133], CALCA [134–136],
and DAPK1 [126,127,137,138] among others are all reviewed in detail
elsewhere [106,109]. Aside from these, one of the most cited epigenetic
hallmarks in CML is increased levels of DNA methylation at the Pa
promoter of ABL1 in mononuclear cells from blood or bone marrow
[130,133,139–145]. The Pa promoter is the second most 5′ promoter of
the ABL1 gene and is normally retained within the chimeric BCR-ABL1
gene of the Ph chromosome in CML. Pa hypermethylation in CP is
highly variable, though significantly different compared to normal
where it is generally unmethylated. The percentage of CP patients
showing increased Pa methylation ranged from as low as 26% [140] up
to between 77 and 81% [130,133,142], although such variations may
be attributable to the different technologies used in different studies.
Both the percentage of patients with Pa methylation and the levels of
methylation has been shown to increase during disease progression
across several studies [133,139,141,142]. However, the degree of Pa
methylation does not correspond to the level of full length BCR-ABL1
transcripts [144] in BP. Taken together, these data add further fuel to
the discussion about the prognostic value of Pa promoter methylation in
CML progression [146].
Recently, the true scope of changes in DNA methylation across CML
methylomes during disease progression has been demonstrated.
Reduced representation bisulfite sequencing (RRBS) was used to survey
methylation at 2.6 million CpG dinucleotides and detected differences
between controls and CML samples in all three phases of disease [147].
Only≈ 600 CpG were found to be differentially methylated in CP
disease compared to healthy controls. However, this number increased
by ten-fold to ≈6500 in BP where 897 genes were dysregulated, with
the majority showing increases in DNA methylation and reduced mRNA
expression. Most of the 897 genes had not previously been identified as
being differentially methylated in CML in two earlier microarray-based
approaches which employed targeted bisulfite sequencing [133,148].
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Table 4
Non-coding RNAs (ncRNAs) dysregulated in CML. Column one: ncRNA name. Column two: class of ncRNA. Column three: putative target gene or competitor RNA (predicted or
experimentally validated). Column four: CML cell type studied (primary patient material or cell lines). Column five: clinical significance as described in the cited reference(s). Column six:
cited reference(s). Abbreviations: PB = peripheral blood; BM = bone marrow; MNC =mononuclear cells; LSC = leukemic stem cell; CP = chronic phase; BP = blast phase;
IFN = interferon; WBC = white blood count; CCR = complete cytogenetic remission; MMR=major molecular response; ND = not determined.
ncRNA Class Putative target/Competitor CML Cell type Clinical significance Reference
lncRNA-BGL3 ceRNA PTEN K562, PB MNC ND [227]
ceRNA network DLGAP1, DST, PHLDB2, SAMD9, STON1,
TRIM6, MAGEA12
K562 disease progression [228]
miR-126 exosomal
miRNA
CXCL12, VCAM1 LAMA84 ND [120]
miR-1908 ND K562 ND [229]
miR-210 EFNA3 K562 ND [230]
miR-298 ND K562 ND [229]
miR-92a ND K562 ND [231]
ncCHES1 lncRNA CHES1 PB MNC dasatinib resistance [232]
ncPRKCB1 PRKCB1 PB MNC dasatinib resistance [232]
ncRNPEP RNPEP PB MNC dasatinib resistance [232]
let-7a,b,d,f,g,i miRNA BCL2L1 K562 ND [151]
miR-100 ND BM MNC CP-CML; imatinib resistance [166]
miR-101 JAK2 PB MNC; K562 CP-CML; imatinib sensitivity [150,233]
miR-103 CDK6; PIK3R1 PB MNC ND [152]
miR-106a ND PB MNC; PB CD34+; K562 CP-CML; BP-CML [149,152]
miR-106b TGFBR2, CCND1 PB MNC CP-CML [150]
miR-107 CRKL K562 ND [151]
miR-10a USF2 among many others BM MNC; BM CD34+ CP-CML [162]
miR-10b CDKN2A K562 ND [151]
miR-125a-5p AKT3 K562 ND [151]
miR-125b AKT3, CDKN2A K562 ND [151]
miR-126 MAPK8, CRK, KRAS, TGFBR2, CCND1,
RUNX1, TP53
PB MNC; BM MNC CP-CML; BP-CML; imatinib
resistance
[150,152,166]
miR-128 CRKL K562 ND [151]
miR130a CCN3 K562; BM stroma; PB MNC CML diagnosis [165,234]
miR-130b TGFBR2, CCN3 K562 ND [151,234]
miR-134 ND BM MNC CP-CML; imatinib resistance [166]
miR-141 ND BM MNC CP-CML; imatinib resistance [166]
miR-142-3p ACVR2A, ANK3, ARHGEF12, CCNJ,
MAP3K11, MYH9, MYO5A, RBM47, RHEB,
RNF38, ZNF618, C18orf25
PB MNC CP-CML; prognostic [163]
miR-144 TGFBR2; SMAD4; RUNX1 PB MNC; K562-R
(R = imatinib resistant)
imatinib resistance [152,235]
miR-145 TGFBR2 K562 ND [151]
miR-146a MAPK8, SMAD4, TP53, C12orf36, MMP16,
NFASC; NFKB1
PB MNC; BM trephines; K562 CP-CML; imatinib response [150,151,163,164]
miR-148b ND PB MNC imatinib discontinuation [236]
miR-150 E2F3, BCR, CBL, CCND1, TP53, MYB,
C12orf36, MMP16, NFASC
PB MNC; BM MNC; BM
CD34+; BM trephines; BM
stroma
CP-CML; BP-CML; relapse;
imatinib response
[150,152,162–165]
miR-151 ND BM MNC; BM CD34+ CP-CML [162]
miR-152 ND PB MNC CP-CML [150]
miR-155 E2F2, E2F3, BCR, CBL, KRAS, SOS1, TGFBR2,
SMAD4, CCND1, PIK3R1, RUNX1, TP53,
JARID2, BACH1
PB MNC; K562; Meg-01; BM
trephines
CP-CML; imatinib response [150,152,164,237]
miR-15a CRKL PB MNC; K562 CP-CML [150,151]
miR-16-1 E2F3, BCR, KRAS, CCND1, TP53 PB MNC CP-CML [150]
miR-17 E2F2, E2F3, CRK, MAPK1, ACVR1B, CCND1,
RUNX1
PB MNC BP-CML [150,152]
miR-17-3p ND K562; PB CD34+ CP-CML [149,152]
miR-17-5p ND K562; PB CD34+ CP-CML [149]
miR181 family MCL1 MYL-R; K562-R
(R = imatinib resistant)
TKI resistance [238]
miR181a RALA, SOS1, PIK3R3 PB MNC; CD34+; K562 imatinib sensitivity [152,239,240]
miR-181c PBX3, HSP90B1,NMT2, RAD21 BM MNC CP-CML; imatinib resistance [241]
miR-183 ABCA1 BM MNC CP-CML; imatinib resistance [166]
miR-188-5p CRKL K562 ND [151]
miR-18a ARHGAP26 K562, PB MNC, PB CD34+ CP-CML [149,192]
miR-18b ARHGAP26 PB MNC CP-CML [192]
miR-19 CCND1 PB MNC BP-CML [152]
miR-191 ND BM MNC CP-CML; imatinib resistance [166]
miR-193a-3p CRKL K562 ND [151]
miR-195 AKT3; IKBKB K562 ND [151]
miR-196b BCR-ABL1, HOXA9 K562; BM MNC CP-CML; imatinib resistance [166,242]
miR-199a ABCC5 BM MNC CP-CML; imatinib resistance [166]
miR-199a-5p IKBKB K562 ND [151]
miR-199b ND PB MNC; BM MNC; K562;
CMLT1
CML with der(9) deletions;
imatinib resistance
[243–245]
(continued on next page)
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Table 4 (continued)
ncRNA Class Putative target/Competitor CML Cell type Clinical significance Reference
miR-199b-5p ACVR2A, ANK3, ARHGEF12, CCNJ,
MAP3K11, MYH9, MYO5A, RBM47, RHEB,
RNF38, ZNF618
PB MNC; BM trephines CP-CML; imatinib response [163,164]
miR-19a RAF1; KRAS; MAPK1; TGFBR2; PIK3R3 PB MNC; K562; PB CD34+ CP-CML; BP-CML [149,151,152]
miR-19b ND PB MNC; PB CD34+ CP-CML; BP-CML [149,152]
miR-203 ABL1; BCR-ABL1 K562; PB MNC; BM MNC imatinib response/sensitivity [246–248]
miR-20a E2F3, BCR, KRAS, TGFBR2, CCND1, RUNX1,
TP53, AKT3
PB MNC; K562; PB CD34+ CP-CML; BP-CML [149–152]
miR-21 E2F1, E2F3, BCR, KRAS, TGFBR2, SMAD3,
SMAD4, CCND1, RUNX1, TP53, PDCD4, BCL2
PB MNC; BM MNC; K562 CP-CML; BP-CML; sensitivity to
arsenic trioxide
[150,151,249–251]
miR-212 ABCG2 PB CD34+; K562 CP-CML; BP-CML; imatinib
response
[149,252]
miR-214 IKBKB K562 ND [151]
miR-215 WNK1, ALCAM, RB1, ZEB2, PTPRT, others plasma imatinib discontinuation [253]
miR-217 DNMT3A K562 TKI resistance [254]
miR-218 IKBKB K562 ND [151]
miR-219-2 ND PB MNC; BM MNC; K562;
CMLT1
CML with der(9) deletions [243–245]
miR-219-5p XIAP K562 ND [62]
miR-22 AKT3 K562 ND [151]
miR-221 CRKL, PI3KR1 PB MNC BP-CML [152]
miR-222 E2F2, CBL, CDKN1B PN MNC BP-CML [152]
miR-224 ND BM MNC CP-CML; imatinib resistance [166]
miR-23a ND BM trephines; BM stroma; PB
MNC; BM MNC
CP-CML; imatinib response/
resistance; CML diagnosis
[164–166,255]
miR-25 HDM2 K562 ND [151]
miR-26a ND BM MNC CP-CML; imatinib resistance [166]
miR-29 family RNAse-L K562 ND [256]
miR-29a SMAD3, CCND1, TP53, TGFBR2, TGFB2 PB MNC; BM MNC; K562 CP-CML; imatinib resistance [150,151,166]
miR-29b ABL1, BCR-ABL1, TGFB2 BM MNC; K562 CP-CML [151,167]
miR-29c TGFB2; ABCB6 BM MNC; K562 ND; CP-CML; imatinib resistance [151,166]
miR-301a,b TGFBR2 K562 ND [151]
miR-30a ATG5, BECLIN1, BCR-ABL1, ABL1 K562; BM MNC imatinib response/sensitivity [257,258]
miR-30b ND BM MNC CP-CML; imatinib resistance [166]
miR-30c ND BM MNC CP-CML; imatinib resistance [166]
miR-30e ABL1, BCR-ABL1 PB MNC; K562 CP-CML; imatinib sensitivity [259]
miR-31 CBL; E2F2 PB MNC; K562; Meg-01 CP-CML [237]
miR-32 HDM2 K562 ND [151]
miR-320a BCR, ABL1 PB MNC CP-CML [260]
miR-323-3p NFKB1 K562 ND [151]
miR-326 SMO BM MNC; BM CD34+ CP-CML; imatinib resistance; BP-
CML
[166,261]
miR-328 PIM1, hnRNP E2 K562 BP-CML [252,262]
miR-330-3p IRF8 PB MNC CP-CML [192]
miR-339-5p HMD2 K562 ND [151]
miR-34a SRC K562; BM MNC ND [263]
miR-362-5p GADD45A PB MNC CP-CML; imatinib response [264]
miR-370 FOXM1; TGFBR2 BM MNC; K562 disease progression; response to
omacetaxine
[151,265]
miR-377 IKBKB K562 ND [151]
miR-409-3p IKBKB K562 ND [151]
miR-411 TGFBR2 K562 ND [151]
miR-422b ND BM trephines; BM MNC CP-CML; imatinib response/
resistance
[164,166]
miR-424 ABL1 PB MNC; K562; BM trephines imatinib sensitivity; atypical CML
(Ph−)
[266,267]
miR-451 BCR-ABL1 PB MNC; K562-R
(R = imatinib resistant)
CP-CML; relapse; TKI response/
failure/resistance; MMR
[150,152,168–170,235]
miR-454 TGFBR2 K562 ND [151]
miR-485-3p CTBP1 K562 ND [151]
miR-486-5p CTBP2, FOXO1, PTEN, ARID4b, AFF3, TWF1, K562; BM CD34+ ND [151,268]
miR-493-5p IL8 K562 imatinib response; CP-CML [269]
miR-494 IKBKB K562 ND [151]
miR-520a ND BM MNC CP-CML; imatinib resistance [166]
miR-520a-5p STAT3 K562 capsaicin sensitivity [270]
miR-562 IRF8 PB MNC CP-CML [192]
miR-564 E2F3, AKT2 PB MNC; K562; Meg-01 CP-CML [237]
miR-568 ND PB MNC CP-CML [150]
miR-579 ARHGAP26 PB MNC CP-CML [192]
miR-607 ND PB MNC CP-CML [150]
miR-625 NFKB1, CDKN2A K562 ND [151]
miR-7 ND BM MNC CP-CML; imatinib resistance [166]
miR-9 ND PB MNC CP-CML; pterocarpanquinone-
LQB-118 sensitivity
[150,271]
miR-92 ND K562; PB CD34+ CP-CML [149]
(continued on next page)
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5.3. MicroRNAs
The miR-17/92 cluster which encodes for six miRNAs processed
from a single transcript is over-expressed in CML cell lines and CD34+
cells from CP and BP [149–151]. However, there are conflicting views
as to whether it is over-expressed in CP [152], with one study showing
that expression of this cluster is only slightly elevated or at normal
levels in PB MNC at diagnosis [152]. However, these conflicting data
can be reconciled by hypothesizing that different miRNAs of the cluster
may be dysregulated during different phases of disease and in different
cell types (CD34+ versus total PB MNCs).
6. Epigenetics in therapeutic response and resistance
6.1. Drug resistance
Genetic aberrations such as point mutations in the BCR-ABL1 fusion
gene [153–155] or additional chromosomal translocations [156,157]
have been strongly implicated in primary and/or secondary resistance
to TKI treatment in CML. However, epigenetic dysregulation is also
increasingly found to play a causal role in TKI resistance and we have
already pointed to several examples (EZH2, PRMT5, SIRT1, MTSS1,
CD70) where combining TKI with novel drugs is able to overcome such
resistance in LSC or progenitor cells in pre-clinical models
[54,63,64,79,91,95]. However, there are other examples supported by
analysis of CML cohorts during TKI therapy.
High expression of PRC1 members is associated with decreased
imatinib sensitivity. In 30 patients with CML, pre- and post-imatinib
bone marrow-derived samples were analyzed for the expression of
PRC1 components [158]. During imatinib treatment, the mRNA ex-
pression of BMI1, PHC3, CBX6, and CBX7 was significantly increased,
and post-treatment levels of CBX6, CBX7 were predictive of the 3-
month response rate to imatinib. In addition, BMI1 expression post-
treatment level measurements improved the predictive power of hOCT-
1 genotyping as a predictor of imatinib response [158].
Increased DNA methylation was linked to down-regulation of BCL2-
interacting mediator (BIM) in 36% of a cohort of 100 CML patients and
was associated with a decrease of optimal imatinib responses [159].
BIM re-expression by 5-azacytidine treatment was shown to be required
for imatinib-induced apoptosis of CML cell lines BV173 and KU812. In
another study, HOXA4 promoter methylation was detected in cells from
95 CML patients and was positively correlated with imatinib resistance
[160], but, here, no data on HOXA4 expression or function were pro-
vided. Two studies showed that DNA hypermethylation were also as-
sociated with resistance to adriamycin and interferon/cytarabine/hy-
droxyurea. In the first, down-regulation of mitochondrial ATPase β-
subunit ATP5 B expression decreased the sensitivity of K562 cells to
adriamycin [161]. Likewise, silencing of p16INK4A and p14ARF ex-
pression by DNA hypermethylation was associated with poor response
to interferon and cytarabine +/− hydroxyurea therapy, which corre-
lated with CML progression [125].
In a more comprehensive study, K562 cells or cells from 120 CML
patients were subjected to analysis of DNA methylation of CpG islands
in the promoters of ten genes (ABL1, CDH13, CDKN2B, DPYS, NPM2,
OSCP1, PDLIM4, PGR-A, PGR-B, TFAP2E) which had previously been
linked to myeloid malignancies [133]. Patients were imatinib-re-
sponsive (n = 30), imatinib-resistant (n = 50), imatinib-intolerant
(n = 10), or imatinib-naïve (n = 30 from the pre-imatinib era). Sample
were taken during CP (n = 65), AP (n = 40), or BP (n = 15). K562
cells showed extensive hypermethylation (15% of total CpG sites) and,
although less extensive, also hypomethylation. There was an overall
inverse correlation of gene expression with promoter methylation. Of
the ten genes analyzed by bisulfite sequencing, five genes showed sig-
nificantly increased fractions of CpG-methylated cases with increasing
disease severity (with an average of 4.5, 6.2, and 6.8 methylated genes
in CP, AP, and BP, respectively). More interestingly, there was a highly
significant increase in the number of methylated genes in cells from
imatinib-resistant or −intolerant vs. −responsive patients [133]. Fi-
nally, promoter methylation of the PDLIM4 gene was significantly in-
versely correlated with survival of the patients [133].
Dramatic down-regulation of miR-150 compared to normal is a
hallmark of CP CML CD34+, mononuclear cells and total leukocytes at
diagnosis [150,152,162–165], and rapid reversal of this during im-
atinib therapy [163] is consistent with imatinib-responders [152]. In-
deed, the degree of down-regulation of several miRNAs can distinguish
imatinib responders from non-responders in drug-naïve CP diagnostic
samples. These include miR-29 cluster [166,167], miR-23a [165,166]
and miR-451 [150,152,168,169]. Furthermore, BCR-ABL1 is a vali-
dated target of miR-451 [170], and this may explain the inverse re-
lationship between the expression of BCR-ABL1 and miR-451 that is
observed in some patients during response to imatinib [169]. However,
further mechanistic studies are required to understand why differing
miRNA levels in diagnostic samples are able to define differing clinical
outcomes.
Epigenomic variability may also play a major role in resistance to
TKI treatment. In a functional assay using single-cell RNA-seq and
GATA-mediated single-cell ATAC-seq in K562 cells, GATA accessibility
was found to show large variations [171], and this was associated with
high variability of CD24, CD44, and CD62 expression. Interestingly,
functional analysis revealed that the CD24hi-expressing but not the
CD24lo-expressing subpopulation showed increased resistance to im-
atinib-induced apoptosis and suppression of colony forming units
[171]. These in vitro data suggest a model by which not only genetic but
also epigenetic variation among subclones may provide the fertile
grounds for therapy resistance, clonal evolution, and, ultimately, pro-
gression of CML during TKI therapy.
6.2. Epigenetic drugs in clinical trials
Given the impact of epigenetic dysregulation in CML, clinical trials
have been conducted to assess the efficacy and tolerability of epigenetic
drugs in CML. In a study of 50 patients with myeloid malignancies who
were treated with decitabine, five patients with CML were included (1
CP, 1 AP, 3 BP). Of these five patients, two achieved a CR and two
patients attained a PR. However, response duration was short (1–9
weeks), there was no correlation with CDKN2B promoter methylation,
and no data on cytogenetic or molecular responses were reported [172].
In a subsequent study, 35 imatinib-resistant CML patients (12 CP, 17
AP, 6 BP) were treated with decitabine [173]. Toxicity was reported as
mild. In CP, 50% of patients achieved a CHR, and the overall response
rate was 83%, with 25% major cytogenetic responses. Again, these
responses were generally short-lived, but occasional long-term re-
sponses occurred, leading to an overall significant superiority of sur-
vival in the decitabine responders vs. non-responders [173].
Table 4 (continued)
ncRNA Class Putative target/Competitor CML Cell type Clinical significance Reference
miR-92a-1 E2F3, BCR, KRAS, SMAD4, CCND1, RUNX1,
TP53
PB MNC CP-CML [150]
miR-96 ND BM MNC; BM CD34+ CP-CML [162]
miRNA network numerous in silico only ND [272]
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Hypomethylation of LINE elements was observed, but this was not
durable [173]. Significantly better overall survival was also reported in
a subsequent study of a combination of decitabine and imatinib in 28
CML patients (18 AP, 10 BP), most of whom were already imatinib-
resistant [174]. In this cohort, 50% of AP and 30% of BP patients
showed overall responses, with 39% and 20% of each group respec-
tively achieving cytogenetic remission. Again, overall survival was
significantly better in the responders, with a plateau during the first 50
weeks, but subsequently declined [174]. In a small case series of eight
patients with imatinib-resistant CML (1 CP, 5 AP, 2 BP), addition of two
HDAC inhibitors, hydralazine and magnesium valproate, to imatinib
therapy resulted in clinical responses during a median of 18 months of
follow-up. Adverse events included mild neurological symptoms but no
grade 3 or 4 toxicities [175]. Thus, addition of HDAC inhibitors may be
beneficial in TKI-refractory CML patients when no other options exist.
Together, the data from these clinical trials show that treatment
with epigenetic drugs can induce objective responses in patients with
CML, even in advanced stages and despite imatinib-refractoriness.
However, these responses are usually not durable, and other treatment
strategies have to be pursued. Currently, not only do several TKI op-
tions exist (i.e. imatinib, dasatinib, nilotinib, bosutinib, and ponatinib),
but novel agents are being tested (i.e. ABL001 [176]), and allogeneic
transplantation remains as a potentially curative option for patients
with advanced or non-responsive disease. The reason for the short-lived
responses may well be our limited understanding of the magnitude and
complexity of epigenetic aberrations and the difficulty to revert these
changes by a single drug.
7. Future prospects
The advent of the genomics era has greatly influenced the under-
standing, diagnosis, and treatment of cancer. Probably among the most
affected are patients with chronic myeloid leukemia (CML). Soon after
the realization of the dramatic success of targeted therapies against the
BCR-ABL1 oncogene, molecular therapies have been spreading to other
cancers, making CML one of the most important and best-understood
paradigmatic malignancies in the field of oncology. Not only has high-
sensitivity PCR monitoring of BCR-ABL1 transcripts long entered clin-
ical practice, leading to important treatment decisions, but the concept
of oncogene addiction of LSC, treatment-emergent oncogenic resistance
due to BCR-ABL1 mutations, and, lately, the concept of TFR and op-
erational cures have all been developed bench-to-bedside-and-back in
the context of CML.
While genetic factors are clearly important, epigenetic modifica-
tions are now increasingly being recognized as crucial mechanisms of
CML pathogenesis, progression, and treatment resistance. With the
currently evolving technologies of whole-genome sequencing, single-
cell RNA-seq, histone modification mapping, and genome-wide DNA
methylation, etc, we are experiencing a time where a much more
comprehensive description of CML biology comes within grasp. It can
be expected that soon the diagnosis of patients with CML will be much
more exact than currently, including sub-clonal analysis and ultra-deep
monitoring. Yet, many questions still remain unanswered and unsolved,
such as the question of optimal treatment of patients with accelerated
and blast phase, the prerequisites for successful treatment dis-
continuation, and the factors for long-term remission. Recently, CML
CD34+ cells, highly enriched for LSC, were demonstrated to be killed
by p53 stabilization combined with BET inhibitor-mediated chromatin
disruption [177]. Furthermore, BET inhibitors can decrease PD-L1 ex-
pression on solid tumor cells [178,179], and it is tempting to speculate
that this downregulation may facilitate activation of immune check-
points and long-term clearance of LSC, similar to suppression of PD1 on
T cells in CML patients with TKI-induced deep molecular remission
[180]. The short-lived duration of responses to epigenetic drugs in the
clinic is also an area that is poorly understood. However, recent studies
suggests that BET inhibitor resistance is likely to be driven by pre-
existing clones which display a high degree of transcriptional plasticity,
making them highly adaptive with the possibility of reversion to BET
sensitivity when treatment is discontinued [181,182]. Such resistant
clones also have altered epigenetic landscapes − pointing to epige-
netic-based resistance mechanisms that will require further investiga-
tion. These findings may also have broader implications for all types of
epigenetic drugs as stand-alone therapies.
Thus, epigenetic factors clearly will continue to play a role in CML
treatment and prognosis, and the elucidation of critical pathways in
cancer initiation, maintenance, and successful elimination of LSC will
continue to benefit from CML research.
Acknowledgements
SK has received grant funding from the German Research
Foundation (DFG KO 2155/2-2; KO 2155/6-1) and the German José
Carreras Leukemia Foundation (DJCLS grant 10/23). DV has received
grant funding from Bloodwise (Ref. 14005, 14033, 14047), the
Wellcome Trust (Ref. GR083755), the Medical Research Council (MR/
K501335/1) and the University of Glasgow.
References
[1] P.C. Nowell, D.A. Hungerford, Chromosome studies in human leukemia: II.
Chronic granulocytic leukemia, J.Natl. Cancer Inst. 27 (1961) 1013–1035.
[2] J.D. Rowley, Letter: a new consistent chromosomal abnormality in chronic mye-
logenous leukaemia identified by quinacrine fluorescence and Giemsa staining,
Nature 243 (1973) 290–293.
[3] N. Heisterkamp, J.R. Stephenson, J. Groffen, P.F. Hansen, A. de Klein,
C.R. Bartram, et al., Localization of the c-ab1 oncogene adjacent to a translocation
break point in chronic myelocytic leukaemia, Nature 306 (1983) 239–242.
[4] M. Rohrbacher, J. Hasford, Epidemiology of chronic myeloid leukaemia (CML),
Best Pract. Res. Clin. Haematol. 22 (2009) 295–302.
[5] S. Giralt, H. Kantarjian, M. Talpaz, The natural history of chronic myelogenous
leukemia in the interferon era, Semin. Hematol. 32 (1995) 152–158.
[6] B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, S. Fanning, et al.,
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl
positive cells, Nat. Med. 2 (1996) 561–566.
[7] S.G. O'Brien, F. Guilhot, R.A. Larson, I. Gathmann, M. Baccarani, F. Cervantes,
et al., Imatinib compared with interferon and low-dose cytarabine for newly di-
agnosed chronic-phase chronic myeloid leukemia, N. Engl. J. Med. 348 (2003)
994–1004.
[8] F.X. Mahon, D. Rea, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, et al.,
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have
maintained complete molecular remission for at least 2 years: the prospective,
multicentre Stop Imatinib (STIM) trial, Lancet Oncol. 11 (2010) 1029–1035.
[9] D.M. Ross, S. Branford, J.F. Seymour, A.P. Schwarer, C. Arthur, D.T. Yeung, et al.,
Safety and efficacy of imatinib cessation for CML patients with stable undetectable
minimal residual disease: results from the TWISTER study, Blood 122 (2013)
515–522.
[10] P. Rousselot, F. Huguet, D. Rea, L. Legros, J.M. Cayuela, O. Maarek, et al., Imatinib
mesylate discontinuation in patients with chronic myelogenous leukemia in
complete molecular remission for more than 2 years, Blood 109 (2007) 58–60.
[11] R. Hehlmann, M.C. Muller, M. Lauseker, B. Hanfstein, A. Fabarius, A. Schreiber,
et al., Deep molecular response is reached by the majority of patients treated with
imatinib, predicts survival, and is achieved more quickly by optimized high-dose
imatinib: results from the randomized CML-Study IV, J. Clin. Oncol. 32 (2014)
(415-U51).
[12] D. Rea, F.E. Nicolini, M. Tulliez, F. Guilhot, J. Guilhot, A. Guerci-Bresler, et al.,
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim
analysis of the STOP 2G-TKI study, Blood 129 (2017) 846–854.
[13] M. Baccarani, M.W. Deininger, G. Rosti, A. Hochhaus, S. Soverini, J.F. Apperley,
et al., European LeukemiaNet recommendations for the management of chronic
myeloid leukemia: 2013, Blood 122 (2013) 872–884.
[14] S. Soverini, A. Hochhaus, F.E. Nicolini, F. Gruber, T. Lange, G. Saglio, et al., BCR-
ABL kinase domain mutation analysis in chronic myeloid leukemia patients
treated with tyrosine kinase inhibitors: recommendations from an expert panel on
behalf of European LeukemiaNet, Blood 118 (2011) 1208–1215.
[15] S. Soverini, C. de Benedittis, M. Mancini, G. Martinelli, Mutations in the BCR-ABL1
kinase domain and elsewhere in chronic myeloid leukemia, Clin. Lymphoma
Myeloma Leuk. 15 (Suppl) (2015) S120–S128.
[16] T.L. Holyoake, D. Vetrie, The chronic myeloid leukemia stem cell: stemming the
tide of persistence, Blood 129 (2017) 1595–1606.
[17] T. Holyoake, X. Jiang, C. Eaves, A. Eaves, Isolation of a highly quiescent sub-
population of primitive leukemic cells in chronic myeloid leukemia, Blood 94
(1999) 2056–2064.
[18] J.C. Chomel, M.L. Bonnet, N. Sorel, A. Bertrand, M.C. Meunier, S. Fichelson, et al.,
Leukemic stem cell persistence in chronic myeloid leukemia patients with sus-
tained undetectable molecular residual disease, Blood 118 (2011) 3657–3660.
S. Koschmieder, D. Vetrie Seminars in Cancer Biology 51 (2018) 180–197
192
[19] S. Chu, T. McDonald, A. Lin, S. Chakraborty, Q. Huang, D.S. Snyder, et al.,
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in
prolonged remission with imatinib treatment, Blood 118 (2011) 5565–5572.
[20] A.S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M.W. Deininger, B.J. Druker,
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite
inhibition of BCR-ABL activity, J. Clin. Invest. 121 (2011) 396–409.
[21] A. Hamilton, G.V. Helgason, M. Schemionek, B. Zhang, S. Myssina, E.K. Allan,
et al., Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase
activity for their survival, Blood 119 (2012) 1501–1510.
[22] S.M. Graham, H.G. Jorgensen, E. Allan, C. Pearson, M.J. Alcorn, L. Richmond,
et al., Primitive, quiescent, Philadelphia-positive stem cells from patients with
chronic myeloid leukemia are insensitive to STI571 in vitro, Blood 99 (2002)
319–325.
[23] M. Copland, A. Hamilton, L.J. Elrick, J.W. Baird, E.K. Allan, N. Jordanides, et al.,
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in
primary CML but does not eliminate the quiescent fraction, Blood 107 (2006)
4532–4539.
[24] H.G. Jorgensen, E.K. Allan, N.E. Jordanides, J.C. Mountford, T.L. Holyoake,
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not in-
duce apoptosis in CD34+ CML cells, Blood 109 (2007) 4016–4019.
[25] A. Avgustinova, S.A. Benitah, Epigenetic control of adult stem cell function, Nat.
Rev. Mol. Cell Biol. 17 (2016) 643–658.
[26] A. Avgustinova, S.A. Benitah, The epigenetics of tumour initiation: cancer stem
cells and their chromatin, Curr. Opin. Genet. Dev. 36 (2016) 8–15.
[27] A.P. Feinberg, R. Ohlsson, S. Henikoff, The epigenetic progenitor origin of human
cancer, Nat. Rev. Genet. 7 (2006) 21–33.
[28] T. Jenuwein, C.D. Allis, Translating the histone code, Science 293 (2001)
1074–1080.
[29] M. Buschbeck, S.B. Hake, Variants of core histones and their roles in cell fate
decisions, development and cancer, Nat. Rev. Mol. Cell Biol. 18 (2017) 299–314.
[30] W.M. Bonner, C.E. Redon, J.S. Dickey, A.J. Nakamura, O.A. Sedelnikova, S. Solier,
et al., OPINION gamma H2AX and cancer, Nat. Rev. Cancer 8 (2008) 957–967.
[31] A. Nagamachi, N. Yamasaki, K. Miyazaki, H. Oda, M. Miyazaki, Z. Honda, et al.,
Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of
chronic myelogenous leukemia in a transgenic mouse model, Cancer Sci. 100
(2009) 1219–1226.
[32] P.J. Cook, B.G. Ju, F. Telese, X.T. Wang, C.K. Glass, M.G. Rosenfeld, Tyrosine
dephosphorylation of H2AX modulates apoptosis and survival decisions, Nature
458 (2009) (591-U53).
[33] A. Xiao, H.T. Li, D. Shechter, S.H. Ahn, L.A. Fabrizio, H. Erdjument-Bromage,
et al., WSTF regulates the H2A: X DNA damage response via a novel tyrosine
kinase activity, Nature 457 (2009) 57–U.
[34] R. Falinski, M. Nieborowska-Skorska, T. Skorski, BCR-ABL1 kinase facilitates lo-
calization of acetylated histones 3 and 4 on DNA double-strand breaks, Leuk. Res.
36 (2012) 241–244.
[35] S. Chakraborty, J.M. Stark, C.L. Sun, H. Modi, W.Y. Chen, T.R. O'Connor, et al.,
Chronic myelogenous leukemia stem and progenitor cells demonstrate chromo-
somal instability related to repeated breakage-fusion-bridge cycles mediated by
increased nonhomologous end joining, Blood 119 (2012) 6187–6197.
[36] M. Nieborowska-Skorska, P.K. Kopinski, R. Ray, G. Hoser, D. Ngaba, S. Flis, et al.,
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leu-
kemia stem cells and primitive progenitors, Blood 119 (2012) 4253–4263.
[37] E. Bolton-Gillespie, M. Schemionek, H.U. Klein, S. Flis, G. Hoser, T. Lange, et al.,
Genomic instability may originate from imatinib-refractory chronic myeloid leu-
kemia stem cells, Blood 121 (2013) 4175–4183.
[38] M. Nieborowska-Skorska, T. Stoklosa, M. Datta, A. Czechowska, L. Rink,
A. Slupianek, et al., ATR-Chk1 axis protects BCR/ABL leukemia cells from the
lethal effect of DNA double-strand breaks, ABBV Cell Cycle 5 (2006) 994–1000.
[39] M.O. Nowicki, R. Falinski, M. Koptyra, A. Slupianek, T. Stoklosa, E. Gloc, et al.,
BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen
species-dependent DNA double-strand breaks, Blood 104 (2004) 3746–3753.
[40] T. Stoklosa, T. Poplawski, M. Koptyra, M. Nieborowska-Skorska, G. Basak,
A. Slupianek, et al., BCR/ABL inhibits mismatch repair to protect from apoptosis
and induce point mutations, Cancer Res. 68 (2008) 2576–2580.
[41] K. Cramer, M. Nieborowska-Skorska, M. Koptyra, A. Slupianek, E.T. Penserga,
C.J. Eaves, et al., BCR/ABL and other kinases from chronic myeloproliferative
disorders stimulate single-strand annealing, an unfaithful DNA double-strand
break repair, Cancer Res. 68 (2008) 6884–6888.
[42] G. Brusa, E. Zuffa, M. Mancini, M. Benvenuti, N. Calonghi, E. Barbieri, et al., P210
Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4
acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic
progenitors, Br. J. Haematol. 132 (2006) 359–369.
[43] M. Kusio-Kobialka, K. Wolanin, P. Podszywalow-Bartnicka, E. Sikora,
K. Skowronek, S.L. McKenna, et al., Increased acetylation of lysine 317/320 of p53
caused by BCR-ABL protects from cytoplasmic translocation of p53 and mi-
tochondria-dependent apoptosis in response to DNA damage, Apoptosis 17 (2012)
950–963.
[44] J.S. Becker, D. Nicetto, K.S. Zaret, H3K9me3-dependent heterochromatin: barrier
to cell fate changes, Trends Genet. 32 (2016) 29–41.
[45] A. Benard, I.J. Goossens-Beumer, A.Q. van Hoesel, W. de Graaf, H. Horati,
H. Putter, et al., Histone trimethylation at H3K4, H3K9 and H4K 20 correlates with
patient survival and tumor recurrence in early-stage colon cancer, BMC Cancer
(2014) 14.
[46] Y. Yokoyama, M. Hieda, Y. Nishioka, A. Matsumoto, S. Higashi, H. Kimura, et al.,
Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes
cell motility in vitro and drives tumor formation in vivo, Cancer Sci. 104 (2013)
889–895.
[47] M. Mancini, E. Zuffa, N. Veljkovic, G. Brusa, P. Corrado, V. Corradi, et al., IPO-
trimethylation of histone H3-lysine9 associated with P210 BCR-ABL tyrosine ki-
nase of chronic myeloid leukaemia, Br. J. Haematol. 141 (2008) 899–902.
[48] E. Lukasova, Z. Koristek, M. Falk, S. Kozubek, S. Grigoryev, M. Kozubek, et al.,
Methylation of histones in myeloid leukemias as a potential marker of granulocyte
abnormalities, J. Leukoc. Biol. 77 (2005) 100–111.
[49] O. Vaute, E. Nicolas, L. Vandel, D. Trouche, Functional and physical interaction
between the histone methyl transferase Suv39H1 and histone deacetylases,
Nucleic Acids Res. 30 (2002) 475–481.
[50] M. Mancini, M. Aluigi, E. Leo, C. Marcozzi, F. Castagnetti, E. Barbieri, et al.,
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive
and resistant to imatinib to Aurora kinase inhibitor MK-0457, Br. J. Haematol. 156
(2012) 265–268.
[51] R.S. Blanc, S. Richard, Arginine methylation the coming of age, Mol. Cell 65
(2017) 8–24.
[52] F. Liu, X.Y. Zhao, F. Perna, L. Wang, P. Koppikar, O. Abdel-Wahab, et al.,
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyl-
transferase activity and promotes myeloproliferation, Cancer Cell 19 (2011)
283–294.
[53] M. Bezzi, S.X. Teo, J. Muller, W.C. Mok, S.K. Sahu, L.A. Vardy, et al., Regulation of
constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA
in sensing defects in the spliceosomal machinery, Gene Dev. 27 (2013)
1903–1916.
[54] Y. Jin, J. Zhou, F. Xu, B. Jin, L. Cui, Y. Wang, et al., Targeting methyltransferase
PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia, J. Clin.
Invest. 126 (2016) 3961–3980.
[55] C. Zhao, J. Blum, A. Chen, H.Y. Kwon, S.H. Jung, J.M. Cook, et al., Loss of beta-
catenin impairs the renewal of normal and CML stem cells in vivo, Cancer Cell 12
(2007) 528–541.
[56] F.H. Heidel, L. Bullinger, Z. Feng, Z. Wang, T.A. Neff, L. Stein, et al., Genetic and
pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem
cells in CML, Cell Stem Cell 10 (2012) 412–424.
[57] J.A. Simon, R.E. Kingston, Mechanisms of Polycomb gene silencing: knowns and
unknowns, Nat. Rev. Mol. Cell Biol. 10 (2009) 697–708.
[58] R. Margueron, D. Reinberg, The Polycomb complex PRC2 and its mark in life,
Nature 469 (2011) 343–349.
[59] D. Pasini, L. Di Croce, Emerging roles for Polycomb proteins in cancer, Curr. Opin.
Genet. Dev. 36 (2016) 50–58.
[60] A. Piunti, D. Pasini, Epigenetic factors in cancer development: polycomb group
proteins, Future Oncol. 7 (2011) 57–75.
[61] R. Qin, K. Li, X. Qi, X. Zhou, L. Wang, P. Zhang, et al., beta-Arrestin1 promotes the
progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation,
Br. J. Cancer 111 (2014) 568–576.
[62] C. Nishioka, T. Ikezoe, J. Yang, A. Yokoyama, BCR/ABL increases EZH2 levels
which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia
cells, Leuk. Res. 45 (2016) 24–32.
[63] H.F. Xie, C. Peng, J.L. Huang, B.E. Li, W. Kim, E.C. Smith, et al., Chronic myelo-
genous leukemia-Initiating cells require polycomb group protein EZH2, Cancer
Discov. 6 (2016) 1237–1247.
[64] M.T. Scott, K. Korfi, P. Saffrey, L.E. Hopcroft, R. Kinstrie, F. Pellicano, et al.,
Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyr-
osine kinase inhibition, Cancer Discov. 6 (2016) 1248–1257.
[65] S. Bozkurt, T. Ozkan, F. Ozmen, Y. Baran, A. Sunguroglu, E. Kansu, The roles of
epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant
chronic myeloid leukemia cells, Hematology 18 (2013) 217–223.
[66] L. Pizzatti, R. Binato, J. Cofre, B.E. Gomes, J. Dobbin, M.E. Haussmann, et al.,
SUZ12 is a candidate target of the non-canonical WNT pathway in the progression
of chronic myeloid leukemia, Gene Chromosome Cancer 49 (2010) 107–118.
[67] D.D. De Carvalho, R. Binato, W.O. Pereira, J.M. Leroy, M.D. Colassanti, R. Proto-
Siqueira, et al., BCR-ABL-mediated upregulation of PRAME is responsible for
knocking down TRAIL in CML patients, Oncogene 30 (2011) 223–233.
[68] M. Merkerova, H. Bruchova, A. Kracmarova, H. Klamova, R. Brdicka, Bmi-1 over-
expression plays a secondary role in chronic myeloid leukemia transformation,
Leuk. Lymphoma 48 (2007) 793–801.
[69] H. Shen, Z. Chen, X. Ding, X. Qi, J. Cen, Y. Wang, et al., BMI1 reprogrammes
histone acetylation and enhances c-fos pathway via directly binding to Zmym3 in
malignant myeloid progression, J. Cell. Mol. Med. 18 (2014) 1004–1017.
[70] M. Kesarwani, Z. Kincaid, A. Gomaa, E. Huber, S. Rohrabaugh, Z. Siddiqui, et al.,
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase in-
hibitor therapy in BCR-ABL-induced leukemia, Nat. Med. 23 (2017) 472–482.
[71] P. Neviani, R. Santhanam, R. Trotta, M. Notari, B.W. Blaser, S. Liu, et al., The
tumor suppressor PP2A is functionally inactivated in blast crisis CML through the
inhibitory activity of the BCR/ABL-regulated SET protein, Cancer Cell 8 (2005)
355–368.
[72] P. Neviani, J.G. Harb, J.J. Oaks, R. Santhanam, C.J. Walker, J.J. Ellis, et al., PP2A-
activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem
cells, J. Clin. Invest. 123 (2013) 4144–4157.
[73] L. Mourgues, V. Imbert, M. Nebout, P. Colosetti, Z. Neffati, P. Lagadec, et al., The
BMI1 polycomb protein represses cyclin G2-induced autophagy to support pro-
liferation in chronic myeloid leukemia cells, Leukemia 29 (2015) 1993–2002.
[74] G.V. Helgason, M. Karvela, T.L. Holyoake, Kill one bird with two stones: potential
efficacy of BCR-ABL and autophagy inhibition in CML, Blood 118 (2011)
2035–2043.
[75] C. Bellodi, M.R. Lidonnici, A. Hamilton, G.V. Helgason, A.R. Soliera, M. Ronchetti,
et al., Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death
S. Koschmieder, D. Vetrie Seminars in Cancer Biology 51 (2018) 180–197
193
in Philadelphia chromosome-positive cells, including primary CML stem cells, J.
Clin. Invest. 119 (2009) 1109–1123.
[76] M. Karvela, P. Baquero, E.M. Kuntz, A. Mukhopadhyay, R. Mitchell, E.K. Allan,
et al., ATG7 regulates energy metabolism, differentiation and survival of
Philadelphia-chromosome-positive cells, Autophagy 12 (2016) 936–948.
[77] S. Rahman, R. Islam, Mammalian Sirt1: insights on its biological functions, Cell
Commun. Signal 9 (2011).
[78] H.F. Yuan, Z.Q. Wang, L. Li, H. Zhang, H. Modi, D. Horne, et al., Activation of
stress response gene SIRT1 by BCR-ABL promotes leukemogenesis, Blood 119
(2012) 1904–1914.
[79] L. Li, L. Wang, L. Li, Z. Wang, Y. Ho, T. McDonald, et al., Activation of p53 by
SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination
with imatinib, Cancer Cell 21 (2012) 266–281.
[80] Z. Wang, H. Yuan, M. Roth, J.M. Stark, R. Bhatia, W.Y. Chen, SIRT1 deacetylase
promotes acquisition of genetic mutations for drug resistance in CML cells,
Oncogene 32 (2013) 589–598.
[81] Z.X. Chen, A.D. Riggs, DNA methylation and demethylation in mammals, J. Biol.
Chem. 286 (2011) 18347–18353.
[82] M. Weber, J.J. Davies, D. Wittig, E.J. Oakeley, M. Haase, W.L. Lam, et al.,
Chromosome-wide and promoter-specific analyses identify sites of differential
DNA methylation in normal and transformed human cells, Nat. Genet. 37 (2005)
853–862.
[83] F. Eckhardt, J. Lewin, R. Cortese, V.K. Rakyan, J. Attwood, M. Burger, et al., DNA
methylation profiling of human chromosomes 6, 20 and 22, Nat. Genet. 38 (2006)
1378–1385.
[84] R.S. Illingworth, A.P. Bird, CpG islands − ‘A rough guide', FEBS Lett. 583 (2009)
1713–1720.
[85] D.N. Cooper, M.H. Taggart, A.P. Bird, Unmethylated domains in vertebrate DNA,
Nucleic Acids Res. 11 (1983) 647–658.
[86] P.A. Jones, Functions of DNA methylation: islands, start sites, gene bodies and
beyond, Nat. Rev. Genet. 13 (2012) 484–492.
[87] W.Y. Chen, S.B. Baylin, Inactivation of tumor suppressor genes− Choice between
genetic and epigenetic routes, ABBV Cell Cycle 4 (2005) 10–12.
[88] P.A. Jones, S.B. Baylin, The epigenomics of cancer, Cell 128 (2007) 683–692.
[89] W.Y. Chen, D.H. Wang, R.W.C. Yen, J.Y. Luo, W. Gu, S.B. Baylin, Tumor sup-
pressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage
responses, Cell 123 (2005) 437–448.
[90] J.P.J. Issa, B.A. Zehnbauer, S.H. Kaufmann, M.A. Biel, S.B. Baylin, HIC1 hy-
permethylation is a late event in hematopoietic neoplasms, Cancer Res. 57 (1997)
1678–1681.
[91] M. Schemionek, O. Herrmann, M.M. Reher, N. Chatain, C. Schubert, I.G. Costa,
et al., Mtss1 is a critical epigenetically regulated tumor suppressor in CML,
Leukemia 30 (2016) 823–832.
[92] Z.F. Chen, A.J. Paquette, D.J. Anderson, NRSF/REST is required in vivo for re-
pression of multiple neuronal target genes during embryogenesis, Nat. Genet. 20
(1998) 136–142.
[93] J.M. Coulson, Transcriptional regulation: cancer, neurons and the REST, Curr.
Biol. 15 (2005) R665–R668.
[94] H. Fan, L. Chen, F. Zhang, Y. Quan, X. Su, X. Qiu, et al., MTSS1, a novel target of
DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular
carcinoma, Oncogene 31 (2012) 2298–2308.
[95] C. Riether, C.M. Schurch, C. Flury, M. Hinterbrandner, L. Druck, A.L. Huguenin,
et al., Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance
in leukemia stem cells by activating Wnt signaling, Sci. Transl. Med. 7 (2015)
(298ra119).
[96] V. Pelechano, L.M. Steinmetz, NON-CODING RNA Gene regulation by antisense
transcription, Nat. Rev. Genet. 14 (2013) 880–893.
[97] K.E. Shearwin, B.P. Callen, J.B. Egan, Transcriptional interference − a crash
course, Trends Genet. 21 (2005) 339–345.
[98] L. He, G.J. Hannon, Micrornas: small RNAs with a big role in gene regulation, Nat.
Rev. Genet. 5 (2004) 522–531.
[99] L. Poliseno, L. Salmena, J.W. Zhang, B. Carver, W.J. Haveman, P.P. Pandolfi, A
coding-independent function of gene and pseudogene mRNAs regulates tumour
biology, Nature 465 (2010) (1033-U90).
[100] R. Denzler, V. Agarwal, J. Stefano, D.P. Bartel, M. Stoffel, Assessing the ceRNA
hypothesis with quantitative measurements of miRNA and target abundance, Mol.
Cell 54 (2014) 766–776.
[101] A.D. Bosson, J.R. Zamudio, P.A. Sharp, Endogenous miRNA and target con-
centrations determine susceptibility to potential ceRNA competition, Mol. Cell 56
(2014) 347–359.
[102] G.A. Calin, C.M. Croce, MicroRNA signatures in human cancers, Nat. Rev. Cancer 6
(2006) 857–866.
[103] J. Hayes, P.P. Peruzzi, S. Lawler, MicroRNAs in cancer: biomarkers, functions and
therapy, Trends Mol. Med. 20 (2014) 460–469.
[104] H. Zhao, D. Wang, W. Du, D. Gu, R. Yang, MicroRNA and leukemia: tiny molecule,
great function, Crit. Rev. Oncol. Hematol. 74 (2010) 149–155.
[105] E.F. Heuston, K.T. Lemon, R.J. Arceci, The beginning of the road for non-Coding
RNAs in normal hematopoiesis and hematologic malignancies, Front. Genet. 2
(2011) 94.
[106] K. Machova Polakova, J. Koblihova, T. Stopka, Role of epigenetics in chronic
myeloid leukemia, Curr. Hematol. Malig. Rep. 8 (2013) 28–36.
[107] J.E. Gordon, J.J. Wong, J.E. Rasko, MicroRNAs in myeloid malignancies, Br. J.
Haematol. 162 (2013) 162–176.
[108] S. Kollinerova, S. Vassanelli, M. Modriansky, The role of miR-29 family members
in malignant hematopoiesis, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc
Czech Repub. 158 (2014) 489–501.
[109] S.M. Tortorella, A. Hung, T.C. Karagiannis, The implication of cancer progenitor
cells and the role of epigenetics in the development of novel therapeutic strategies
for chronic myeloid leukemia, Antioxid. Redox Signal. 22 (2015) 1425–1462.
[110] K. Kotagama, Y. Chang, M. Mangone, miRNAs as biomarkers in chronic myelo-
genous leukemia, Drug Dev. Res. 76 (2015) 278–285.
[111] C. Di Stefano, G. Mirone, S. Perna, G. Marfe, The roles of microRNAs in the pa-
thogenesis and drug resistance of chronic myelogenous leukemia (Review), Oncol.
Rep. 35 (2016) 614–624.
[112] C. Corrado, S. Raimondo, A. Chiesi, F. Ciccia, G. De Leo, R. Alessandro, Exosomes
as intercellular signaling organelles involved in health and disease: basic science
and clinical applications, Int. J. Mol. Sci. 14 (2013) 5338–5366.
[113] A. Montecalvo, A.T. Larregina, W.J. Shufesky, D.B. Stolz, M.L.G. Sullivan,
J.M. Karlsson, et al., Mechanism of transfer of functional microRNAs between
mouse dendritic cells via exosomes, Blood 119 (2012) 756–766.
[114] T. Gagliano, T. Simon, G. Giamas, miRNA transported by exosomes: a key ma-
chinery in tumor microenvironment mediated chemoresistance, Transl Cancer
Res. 5 (2016) S1479–S1482.
[115] L. Jin, Y. Tabe, S. Konoplev, Y. Xu, C.E. Leysath, H. Lu, et al., CXCR4 up-regulation
by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone
marrow stroma and promotes survival of quiescent CML cells, Mol. Cancer Ther. 7
(2008) 48–58.
[116] F. Vianello, F. Villanova, V. Tisato, S. Lymperi, K.K. Ho, A.R. Gomes, et al., Bone
marrow mesenchymal stromal cells non-selectively protect chronic myeloid leu-
kemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis,
Haematologica 95 (2010) 1081–1089.
[117] F. Dillmann, M.R. Veldwijk, S. Laufs, M. Sperandio, G. Calandra, F. Wenz, et al.,
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact
in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+
cell to Imatinib and Nilotinib, Leuk. Lymphoma 50 (2009) 1676–1686.
[118] E. Weisberg, A.K. Azab, P.W. Manley, A.L. Kung, A.L. Christie, R. Bronson, et al.,
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow
microenvironment and sensitizes them to nilotinib, Leukemia 26 (2012) 985–990.
[119] A. Ptasznik, E. Urbanowska, S. Chinta, M.A. Costa, B.A. Katz, M.A. Stanislaus,
et al., Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src
family kinase in human leukemia cells, J. Exp. Med. 196 (2002) 667–678.
[120] S. Taverna, V. Amodeo, L. Saieva, A. Russo, M. Giallombardo, G. De Leo, et al.,
Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and mi-
gratory abilities of chronic myelogenous leukemia cells, Mol. Cancer 13 (2014)
169.
[121] M. Mohty, A.S.M. Yong, R.M. Szydlo, J.F. Apperley, J.V. Melo, The polycomb
group BMI1 gene is a molecular marker for predicting prognosis of chronic mye-
loid leukemia, Blood 110 (2007) 380–383.
[122] S. Koschmieder, B. Gottgens, P. Zhang, J. Iwasaki-Arai, K. Akashi, J.L. Kutok,
et al., Inducible chronic phase of myeloid leukemia with expansion of hemato-
poietic stem cells in a transgenic model of BCR-ABL leukemogenesis, Blood 105
(2005) 324–334.
[123] A. Sengupta, A.M. Ficker, S.K. Dunn, M. Madhu, J.A. Cancelas, Bmi1 reprograms
CML B-lymphoid progenitors to become B-ALL-initiating cells, Blood 119 (2012)
494–502.
[124] A. Rizo, S.J. Horton, S. Olthof, B. Dontje, A. Ausema, R. van Os, et al., BMI1
collaborates with BCR-ABL in leukemic transformation of human CD34(+) cells,
Blood 116 (2010) 4621–4630.
[125] E. Nagy, Z. Beck, A. Kiss, E. Csoma, B. Telek, J. Konya, et al., Frequent methylation
of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid
leukaemia from its chronic to accelerated phase, Eur. J. Cancer 39 (2003)
2298–2305.
[126] E. Uehara, S. Takeuchi, Y. Yang, T. Fukumoto, Y. Matsuhashi, T. Tamura, et al.,
Aberrant methylation in promoter-associated CpG islands of multiple genes in
chronic myelogenous leukemia blast crisis, Oncol. Lett. 3 (2012) 190–192.
[127] K. Bodoor, Y. Haddad, A. Alkhateeb, A. Al-Abbadi, M. Dowairi, A. Magableh, et al.,
DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK
and TMS1) genes in peripheral blood of leukemia patients, Asian Pac. J. Cancer
Prev. 15 (2014) 75–84.
[128] S. Kusy, M. Cividin, N. Sorel, F. Brizard, F. Guilhot, A. Brizard, et al., p14ARF,
p15INK4b, and p16INK4a methylation status in chronic myelogenous leukemia,
Blood 101 (2003) 374–375.
[129] S. Kusy, C.J. Larsen, J. Roche, p14ARF, p15INK4b and p16INK4a methylation
status in chronic myelogenous leukemia, Leuk. Lymphoma 45 (2004) 1989–1994.
[130] T.T. Nguyen, A.F. Mohrbacher, Y.C. Tsai, J. Groffen, N. Heisterkamp,
P.W. Nichols, et al., Quantitative measure of c-abl and p15 methylation in chronic
myelogenous leukemia: biological implications, Blood 95 (2000) 2990–2992.
[131] C. Nguyen, G. Liang, T.T. Nguyen, D. Tsao-Wei, S. Groshen, M. Lubbert, et al.,
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and
neoplastic cells, J. Natl. Cancer Inst. 93 (2001) 1465–1472.
[132] J.J. Janssen, F. Denkers, P. Valk, J.J. Cornelissen, G.J. Schuurhuis,
G.J. Ossenkoppele, Methylation patterns in CD34 positive chronic myeloid leu-
kemia blast crisis cells, Haematologica 95 (2010) 1036–1037.
[133] J. Jelinek, V. Gharibyan, M.R. Estecio, K. Kondo, R. He, W. Chung, et al., Aberrant
DNA methylation is associated with disease progression, resistance to imatinib and
shortened survival in chronic myelogenous leukemia, PLoS One 6 (2011) e22110.
[134] B.D. Nelkin, D. Przepiorka, P.J. Burke, E.D. Thomas, S.B. Baylin, Abnormal me-
thylation of the calcitonin gene marks progression of chronic myelogenous leu-
kemia, Blood 77 (1991) 2431–2434.
[135] T. Malinen, A. Palotie, S. Pakkala, L. Peltonen, T. Ruutu, S.E. Jansson, Acceleration
of chronic myeloid leukemia correlates with calcitonin gene hypermethylation,
Blood 77 (1991) 2435–2440.
S. Koschmieder, D. Vetrie Seminars in Cancer Biology 51 (2018) 180–197
194
[136] K.I. Mills, B.A. Guinn, V.A. Walsh, A.K. Burnett, Increasing methylation of the
calcitonin gene during disease progression in sequential samples from CML pa-
tients, Leuk. Res. 20 (1996) 771–775.
[137] J. Qian, Y.L. Wang, J. Lin, D.M. Yao, W.R. Xu, C.Y. Wu, Aberrant methylation of
the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid
leukemia, Eur. J. Haematol. 82 (2009) 119–123.
[138] S. Celik, D. Akcora, T. Ozkan, N. Varol, S. Aydos, A. Sunguroglu, Methylation
analysis of the DAPK1 gene in imatinib-resistant chronic myeloid leukemia pa-
tients, Oncol. Lett. 9 (2015) 399–404.
[139] M. Zion, D. Ben-Yehuda, A. Avraham, O. Cohen, M. Wetzler, D. Melloul, et al.,
Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic
myelogenous leukemia, Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 10722–10726.
[140] D. Ben-Yehuda, S. Krichevsky, E.A. Rachmilewitz, A. Avraham, G.A. Palumbo,
F. Frassoni, et al., Molecular follow-up of disease progression and interferon
therapy in chronic myelocytic leukemia, Blood 90 (1997) 4918–4923.
[141] F.A. Asimakopoulos, P.J. Shteper, S. Krichevsky, E. Fibach, A. Polliack,
E. Rachmilewitz, et al., ABL1 methylation is a distinct molecular event associated
with clonal evolution of chronic myeloid leukemia, Blood 94 (1999) 2452–2460.
[142] J.P. Issa, H. Kantarjian, A. Mohan, S. O'Brien, J. Cortes, S. Pierce, et al.,
Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of
prognostic significance, Blood 93 (1999) 2075–2080.
[143] E.A. Rachmilewitz, The role of methylation in CML, Przegl. Lek. 57 (Suppl. 1)
(2000) 25–26.
[144] B. Sun, G. Jiang, M.A. Zaydan, V.F. La Russa, H. Safah, M. Ehrlich, ABL1 promoter
methylation can exist independently of BCR-ABL transcription in chronic myeloid
leukemia hematopoietic progenitors, Cancer Res. 61 (2001) 6931–6937.
[145] P.J. Shteper, Z. Siegfried, F.A. Asimakopoulos, G.A. Palumbo, E.A. Rachmilewitz,
Y. Ben-Neriah, et al., ABL1 methylation in Ph-positive ALL is exclusively asso-
ciated with the P210 form of BCR-ABL, Leukemia 15 (2001) 575–582.
[146] F.A. Asimakopoulos, P.J. Shteper, E. Fibach, E. Rachmilewitz, Y. Ben-Neriah,
D. Ben-Yehuda, Prognostic significance of c-ABL methylation in chronic myelo-
genous leukemia: still an open question, Blood 94 (1999) 1141.
[147] G. Heller, T. Topakian, C. Altenberger, S. Cerny-Reiterer, S. Herndlhofer,
B. Ziegler, et al., Next-generation sequencing identifies major DNA methylation
changes during progression of Ph+ chronic myeloid leukemia, Leukemia 30
(2016) 1861–1868.
[148] T. Dunwell, L. Hesson, T.A. Rauch, L.H. Wang, R.E. Clark, A. Dallol, et al., A
genome-wide screen identifies frequently methylated genes in haematological and
epithelial cancers, Mol. Cancer 9 (2010).
[149] L. Venturini, K. Battmer, M. Castoldi, B. Schultheis, A. Hochhaus,
M.U. Muckenthaler, et al., Expression of the miR-17-92 polycistron in chronic
myeloid leukemia (CML) CD34(+) cells, Blood 109 (2007) 4399–4405.
[150] P. Fallah, N. Amirizadeh, B. Poopak, G. Toogeh, E. Arefian, F. Kohram, et al.,
Expression pattern of key microRNAs in patients with newly diagnosed chronic
myeloid leukemia in chronic phase, Int. J. Lab. Hematol. 37 (2015) 560–568.
[151] Q. Xiong, Y. Yang, H. Wang, J. Li, S. Wang, Y. Li, et al., Characterization of
miRNomes in acute and chronic myeloid leukemia cell lines, Genomics Proteomics
Bioinformatics 12 (2014) 79–91.
[152] K. Machova Polakova, T. Lopotova, H. Klamova, P. Burda, M. Trneny, T. Stopka,
et al., Expression patterns of microRNAs associated with CML phases and their
disease related targets, Mol. Cancer 10 (2011) 41.
[153] M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P.N. Rao, et al.,
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or
amplification, Science 293 (2001) 876–880.
[154] C. Roche-Lestienne, V. Soenen-Cornu, N. Grardel-Duflos, J.L. Lai, N. Philippe,
T. Facon, et al., Several types of mutations of the Abl gene can be found in chronic
myeloid leukemia patients resistant to ST157, and they can pre-exist to the onset
of treatment, Blood 100 (2002) 1014–1018.
[155] S. Roumiantsev, N.P. Shah, M.E. Gorre, J. Nicoll, B.B. Brasher, C.L. Sawyers, et al.,
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by
mutation of Tyr-253 in the Abl kinase domain P-loop, Proc. Natl. Acad. Sci. U. S. A.
99 (2002) 10700–10705.
[156] T.D. Kim, S. Turkmen, M. Schwarz, G. Koca, H. Nogai, C. Bommer, et al., Impact of
additional chromosomal aberrations and BCR-ABL kinase domain mutations on
the response to nilotinib in Philadelphia chromosome-positive chronic myeloid
leukemia, Haematol.—Hematol. J. 95 (2010) 582–588.
[157] S. Luatti, F. Castagnetti, G. Marzocchi, C. Baldazzi, G. Gugliotta, I. Iacobucci, et al.,
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse
prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on
CML analysis, Blood 120 (2012) 761–767.
[158] F. Crea, A. Di Paolo, H.H. Liu, M. Polillo, P.L. Clermont, F. Guerrini, et al.,
Polycomb genes are associated with response to imatinib in chronic myeloid
leukemia, Epigenomics 7 (2015) 757–765.
[159] E. San Jose-Eneriz, X. Agirre, A. Jimenez-Velasco, L. Cordeu, V. Martin,
V. Arqueros, et al., Epigenetic down-regulation of BIM expression is associated
with reduced optimal responses to imatinib treatment in chronic myeloid leu-
kaemia, Eur. J. Cancer 45 (2009) 1877–1889.
[160] M.H. Elias, A.A. Baba, A. Husin, S. Sulong, R. Hassan, G.A. Sim, et al., HOXA4 gene
promoter hypermethylation as an epigenetic mechanism mediating resistance to
imatinib mesylate in chronic myeloid leukemia patients, BioMed Res. Int. (2013).
[161] R.J. Li, G.S. Zhang, Y.H. Chen, J.F. Zhu, Q.J. Lu, F.J. Gong, et al., Down-regulation
of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid
leukemia is associated with multidrug resistance, Ann. Oncol. 21 (2010)
1506–1514.
[162] X. Agirre, A. Jimenez-Velasco, E.S. Jose-Eneriz, L. Garate, E. Bandres, L. Cordeu,
et al., Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34(+)
cells increases USF2-mediated cell growth, Mol. Cancer Res. 6 (2008) 1830–1840.
[163] S. Flamant, W. Ritchie, J. Guilhot, J. Holst, M.L. Bonnet, J.C. Chomel, et al., Micro-
RNA response to imatinib mesylate in patients with chronic myeloid leukemia,
Haematologica 95 (2010) 1325–1333.
[164] N. Gebauer, V. Bernard, W. Gebauer, A.C. Feller, H. Merz, miRNA expression
correlated with morphological findings in chronic myeloid leukemia treated with
imatinib mesylate, Acta Haematol. 131 (2014) 11–15.
[165] X. Zhu, Z. Lin, J. Du, X. Zhou, L. Yang, G. Liu, Studies on microRNAs that are
correlated with the cancer stem cells in chronic myeloid leukemia, Mol. Cell.
Biochem. 390 (2014) 75–84.
[166] E. San Jose-Eneriz, J. Roman-Gomez, A. Jimenez-Velasco, L. Garate, V. Martin,
L. Cordeu, et al., MicroRNA expression profiling in Imatinib-resistant Chronic
Myeloid Leukemia patients without clinically significant ABL1-mutations, Mol.
Cancer 8 (2009) 69.
[167] Y. Li, H. Wang, K. Tao, Q. Xiao, Z. Huang, L. Zhong, et al., miR-29b suppresses
CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein,
Exp. Cell Res. 319 (2013) 1094–1101.
[168] T. Lopotova, M. Zackova, H. Klamova, J. Moravcova, MicroRNA-451 in chronic
myeloid leukemia: miR-451-BCR-ABL regulatory loop, Leuk. Res. 35 (2011)
974–977.
[169] V. Scholl, R. Hassan, I.R. Zalcberg, miRNA-451: a putative predictor marker of
Imatinib therapy response in chronic myeloid leukemia, Leuk. Res. 36 (2012)
119–121.
[170] N. Iraci, E. Valli, S. Gherardi, S. Soverini, T. Kalebic, M. Baccarani, et al.,
Suppression of bcr-Abl expression in CML by a panel of miRNAs, Blood 114 (2009)
351.
[171] U.M. Litzenburger, J.D. Buenrostro, B.J. Wu, Y. Shen, N.C. Sheffield, A. Kathiria,
et al., Single-cell epigenomic variability reveals functional cancer heterogeneity,
Genome Biol. (2017) 2017.
[172] J.P.J. Issa, G. Garcia-Manero, F.J. Giles, R. Mannari, D. Thomas, S. Faderl, et al.,
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating
agent 5-aza-2 '-deoxycytidine (decitabine) in hematopoietic malignancies, Blood
103 (2004) 1635–1640.
[173] J.P. Issa, V. Gharibyan, J. Cortes, J. Jelinek, G. Morris, S. Verstovsek, et al., Phase
II study of low-dose decitabine in patients with chronic myelogenous leukemia
resistant to imatinib mesylate, J. Clin. Oncol. 23 (2005) 3948–3956.
[174] Y. Oki, H.M. Kantarjian, V. Gharibyan, D. Jones, S. O'Brien, S. Verstovsek, et al.,
Phase II study of low-dose decitabine in combination with imatinib mesylate in
patients with accelerated or myeloid blastic phase of chronic myelogenous leu-
kemia, Cancer 109 (2007) 899–906.
[175] E. Cervera, M. Candelaria, O. Lopez-Navarro, J. Labardini, A. Gonzalez-Fierro,
L. Taja-Chayeb, et al., Epigenetic therapy with hydralazine and magnesium
valproate reverses imatinib resistance in patients with chronic myeloid leukemia,
Clin. Lymphoma Myeloma Leuk. 12 (2012) 207–212.
[176] A.A. Wylie, J. Schoepfer, W. Jahnke, S.W. Cowan-Jacob, A. Loo, P. Furet, et al.,
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1, Nature 543
(2017) 733-.
[177] S.A. Abraham, L.E. Hopcroft, E. Carrick, M.E. Drotar, K. Dunn, A.J. Williamson,
et al., Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells,
Nature 534 (2016) 341–346.
[178] H.R. Zhu, F. Bengsch, N. Svoronos, M.R. Rutkowski, B.G. Bitler, M.J. Allegrezza,
et al., BET bromodomain inhibition promotes anti-tumor immunity by suppressing
PD-L1 expression, Cell Rep. 16 (2016) 2829–2837.
[179] S.J. Hogg, S.J. Vervoort, S. Deswal, C.J. Ott, J. Li, L.A. Cluse, et al., BET-bromo-
domain inhibitors engage the host immune system and regulate expression of the
immune checkpoint ligand PD-L1, Cell Rep. 18 (2017) 2162–2174.
[180] A. Hughes, J. Clarson, C. Tang, L. Vidovic, D.L. White, T.P. Hughes, et al., CML
patients with deep molecular responses to TKI have restored immune effectors and
decreased PD-1 and immune suppressors, Blood 129 (2017) 1166–1176.
[181] B. Knoechel, J.E. Roderick, K.E. Williamson, J. Zhu, J.G. Lohr, M.J. Cotton, et al.,
An epigenetic mechanism of resistance to targeted therapy in T cell acute lym-
phoblastic leukemia, Nat. Genet. 46 (2014) 364-.
[182] C.Y. Fong, O. Gilan, E.Y.N. Lam, A.F. Rubin, S. Ftouni, D. Tyler, et al., BET in-
hibitor resistance emerges from leukaemia stem cells, Nature 525 (2015) 538–542.
[183] T. Kim, M.S. Tyndel, H.J. Kim, J.S. Ahn, S.H. Choi, H.J. Park, et al., Spectrum of
somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase
inhibitor therapy, Blood 129 (2017) 38–47.
[184] M. Schmidt, J. Rinke, V. Schafer, S. Schnittger, A. Kohlmann, E. Obstfelder, et al.,
Molecular-defined clonal evolution in patients with chronic myeloid leukemia
independent of the BCR-ABL status, Leukemia 28 (2014) 2292–2299.
[185] C. Roche-Lestienne, A. Marceau, E. Labis, O. Nibourel, V. Coiteux, J. Guilhot,
et al., Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid
leukemia, Leukemia 25 (2011) 1661–1664.
[186] V. Grossmann, A. Kohlmann, M. Zenger, S. Schindela, C. Eder, S. Weissmann,
et al., A deep-sequencing study of chronic myeloid leukemia patients in blast crisis
(BC-CML) detects mutations in 76.9% of cases, Leukemia 25 (2011) 557–560.
[187] H. Makishima, A.M. Jankowska, M.A. McDevitt, C. O'Keefe, S. Dujardin,
H. Cazzolli, et al., CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional
chromosomal aberrations constitute molecular events in chronic myelogenous
leukemia, Blood 117 (2011) E198–E206.
[188] S. Soverini, J. Score, I. Iacobucci, A. Poerio, A. Lonetti, A. Gnani, et al., IDH2
somatic mutations in chronic myeloid leukemia patients in blast crisis, Leukemia
25 (2011) 178–181.
[189] C. Nakaseko, J. Takeda, E. Togasaki, K. Yoshida, Y. Shiozawa, M. Takeuchi, et al.,
Somatic mutations in newly-diagnosed chronic myeloid leukemia detected by
whole-exome sequencing, Haematologica 101 (2016) 232–233.
S. Koschmieder, D. Vetrie Seminars in Cancer Biology 51 (2018) 180–197
195
[190] E. Togasaki, J. Takeda, K. Yoshida, Y. Shiozawa, M. Takeuchi, M. Oshima, et al.,
Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic
myeloid leukemia, Blood Cancer J. 7 (2017).
[191] J. Menezes, R.N. Salgado, F. Acquadro, G. Gomez-Lopez, M.C. Carralero,
A. Barroso, et al., ASXL1, TP53 and IKZF3 mutations are present in the chronic
phase and blast crisis of chronic myeloid leukemia, Blood Cancer J. (2013) 3.
[192] A. Dzikiewicz-Krawczyk, A. Macieja, E. Maly, D. Januszkiewicz-Lewandowska,
M. Mosor, M. Fichna, et al., Polymorphisms in microRNA target sites modulate risk
of lymphoblastic and myeloid leukemias and affect microRNA binding, J.
Hematol. Oncol. 7 (2014) 43.
[193] J. Bhattacharyya, K. Mihara, S. Yasunaga, H. Tanaka, M. Hoshi, Y. Takihara, et al.,
BMI-1 expression is enhanced through transcriptional and posttranscriptional
regulation during the progression of chronic myeloid leukemia, Ann. Hematol. 88
(2009) 333–340.
[194] Y.H. Lin, C.C. Lee, F.R. Chang, W.H. Chang, Y.C. Wu, J.G. Chang, 16-hydro-
xycleroda-3,13-dien-15,16-olide regulates the expression of histone-modifying
enzymes PRC2 complex and induces apoptosis in CML K562 cells, Life Sci. 89
(2011) 886–895.
[195] Y.J. Zhang, C.R. Lu, Y. Cao, Y. Luo, R.F. Bao, S. Yan, et al., Imatinib induces H2AX
phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via
caspase-3/Mst1 pathway, Acta Pharmacol. Sin. 33 (2012) 551–557.
[196] Y. Dong, M. Xiong, L. Duan, Z. Liu, T. Niu, Y. Luo, et al., H2AX phosphorylation
regulated by p38 is involved in Bim expression and apoptosis in chronic myelo-
genous leukemia cells induced by imatinib, Apoptosis 19 (2014) 1281–1292.
[197] I. Rajan, P.R. Jayasree, P.R. Kumar, Zerumbone induces mitochondria-mediated
apoptosis via increased calcium, generation of reactive oxygen species and upre-
gulation of soluble histone H2AX in K562 chronic myelogenous leukemia cells,
Tumour Biol. 36 (2015) 8479–8489.
[198] X.P. Wu, M. Xiong, C.S. Xu, L.N. Duan, Y.Q. Dong, Y. Luo, et al., Resveratrol in-
duces apoptosis of human chronic myelogenous leukemia cells in vitro through
p38 and JNK-regulated H2AX phosphorylation, Acta Pharmacol. Sin. 36 (2015)
353–361.
[199] S. Correa, R. Binato, B. Du Rocher, G. Ferreira, P. Cappelletti, S. Soares-Lima,
et al., ABCB1 regulation through LRPPRC is influenced by the methylation status
of the GC −100 box in its promoter, Epigenetics 9 (2014) 1172–1183.
[200] E. Leo, M. Mancini, M. Aluigi, F. Castagnetti, G. Martinelli, E. Barbieri, et al., DNA
hypermethylation promotes the low expression of pro-apoptotic BCL2L11 asso-
ciated with BCR-ABL1 fusion gene of chronic myeloid leukaemia, Br. J. Haematol.
159 (2012) 373–376.
[201] Y. Koh, D.Y. Kim, S.H. Park, H.M. Byun, I. Kim, S.S. Yoon, et al., Increased BCR
promoter DNA methylation status strongly correlates with favorable response to
imatinib in chronic myeloid leukemia patients, Oncol. Lett. 2 (2011) 181–187.
[202] E. Leo, M. Mancini, F. Castagnetti, G. Gugliotta, M.A. Santucci, G. Martinelli, DNA
methyltransferase 1 drives transcriptional down-modulation of beta catenin an-
tagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leu-
kemia, J. Cell. Biochem. 116 (2015) 589–597.
[203] S. Annamaneni, S. Kagita, M. Gorre, R.R. Digumarti, V. Satti, M.R. Battini,
Methylation status of CEBPA gene promoter in chronic myeloid leukemia,
Hematology 19 (2014) 42–44.
[204] M. Samaiya, S. Bakhshi, A.A. Shukla, L. Kumar, S.S. Chauhan, Epigenetic regula-
tion of cathepsin L expression in chronic myeloid leukaemia, J. Cell. Mol. Med. 15
(2011) 2189–2199.
[205] Y.L. Wang, J. Qian, J. Lin, D.M. Yao, Z. Qian, Z.H. Zhu, et al., Methylation status of
DDIT3 gene in chronic myeloid leukemia, J. Exp. Clin. Cancer Res. 29 (2010) 54.
[206] J.D. Zhou, Y.X. Wang, T.J. Zhang, D.Q. Yang, D.M. Yao, H. Guo, et al., Epigenetic
inactivation of DLX4 is associated with disease progression in chronic myeloid
leukemia, Biochem. Biophys. Res. Commun. 463 (2015) 1250–1256.
[207] G.S. Randhawa, H. Cui, J.A. Barletta, L.Z. Strichman-Almashanu, M. Talpaz,
H. Kantarjian, et al., Loss of imprinting in disease progression in chronic myelo-
genous leukemia, Blood 91 (1998) 3144–3147.
[208] M.Y. Yang, T.C. Liu, J.G. Chang, P.M. Lin, S.F. Lin, JunB gene expression is in-
activated by methylation in chronic myeloid leukemia, Blood 101 (2003)
3205–3211.
[209] C.E. Litz, A.N. Goldfarb, J.G. Strickler, R.D. Brunning, Presence of cell lineage-
specific hypomethylated sites in the major breakpoint cluster region, Cancer Res.
50 (1990) 4984–4990.
[210] C.E. Litz, J.A. Vos, C.M. Copenhaver, Aberrant methylation of the major break-
point cluster region in chronic myeloid leukemia, Blood 88 (1996) 2241–2249.
[211] X.Q. Ge, K. Tanaka, A. Mansyur, H. Tazawa, K. Iwato, T. Kyo, et al., Possible
prediction of myeloid and lymphoid crises in chronic myelocytic leukemia at onset
by determining the methylation status of the major breakpoint cluster region,
Cancer Genet. Cytogenet. 126 (2001) 102–110.
[212] X. Agirre, J. Roman-Gomez, I. Vazquez, A. Jimenez-Velasco, L. Garate, C. Montiel-
Duarte, et al., Abnormal methylation of the common PARK2 and PACRG promoter
is associated with downregulation of gene expression in acute lymphoblastic
leukemia and chronic myeloid leukemia, Int. J. Cancer 118 (2006) 1945–1953.
[213] M.Y. Yang, J.G. Chang, P.M. Lin, K.P. Tang, Y.H. Chen, H.Y. Lin, et al.,
Downregulation of circadian clock genes in chronic myeloid leukemia: alternative
methylation pattern of hPER3, Cancer Sci. 97 (2006) 1298–1307.
[214] J.J. Song, Q. Liu, Y. Li, Z.S. Yang, L. Yang, T.X. Xiang, et al., Epigenetic in-
activation of PLCD1 in chronic myeloid leukemia, Int. J. Mol. Med. 30 (2012)
179–184.
[215] J. Roman-Gomez, A. Jimenez-Velasco, X. Agirre, J.A. Castillejo, G. Navarro,
E.S. Jose-Eneriz, et al., Epigenetic regulation of PRAME gene in chronic myeloid
leukemia, Leuk. Res. 31 (2007) 1521–1528.
[216] Y. Li, L. Yang, Y. Pan, J. Yang, Y. Shang, J. Luo, Methylation and decreased
expression of SHP-1 are related to disease progression in chronic myelogenous
leukemia, Oncol. Rep. 31 (2014) 2438–2446.
[217] A. Avramouli, S. Tsochas, E. Mandala, E. Katodritou, M. Ioannou, K. Ritis, et al.,
Methylation status of RASSF1A in patients with chronic myeloid leukemia, Leuk.
Res. 33 (2009) 1130–1132.
[218] M. Pehlivan, Z. Sercan, H.O. Sercan, sFRP1 promoter methylation is associated
with persistent Philadelphia chromosome in chronic myeloid leukemia, Leuk. Res.
33 (2009) 1062–1067.
[219] T.C. Liu, S.F. Lin, J.G. Chang, M.Y. Yang, S.Y. Hung, C.S. Chang, Epigenetic al-
teration of the SOCS1 gene in chronic myeloid leukaemia, Br. J. Haematol. 123
(2003) 654–661.
[220] H.A. Al-Jamal, S.A. Jusoh, A.C. Yong, J.M. Asan, R. Hassan, M.F. Johan, Silencing
of suppressor of cytokine signaling-3 due to methylation results in phosphoryla-
tion of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia
cells, Asian Pac. J. Cancer Prev. 15 (2014) 4555–4561.
[221] H. Yang, H. Liang, J.S. Yan, R. Tao, S.G. Hao, L.Y. Ma, Down-regulation of he-
matopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid
leukemia, Int. J. Hematol. 96 (2012) 65–73.
[222] S.L. Rogers, Y. Zhao, X. Jiang, C.J. Eaves, D.L. Mager, A. Rouhi, Expression of the
leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic
myeloid leukemia, Mol. Cancer 9 (2010) 41.
[223] Q. Chen, J. Lin, J. Qian, Z.Q. Deng, W. Qian, J. Yang, et al., The methylation status
of the DDX43 promoter in Chinese patients with chronic myeloid leukemia, Genet.
Test. Mol. Biomark. 17 (2013) 508–511.
[224] H.K. Wu, M.D. Minden, Transcriptional activation of human LIM-HOX gene hLH-2
in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl, Biochem.
Biophys. Res. Commun. 234 (1997) 742–747.
[225] J. Roman-Gomez, A. Jimenez-Velasco, X. Agirre, J.A. Castillejo, G. Navarro, E. San
Jose-Eneriz, et al., Repetitive DNA hypomethylation in the advanced phase of
chronic myeloid leukemia, Leuk. Res. 32 (2008) 487–490.
[226] O. Hatirnaz, U. Ure, C. Ar, C. Akyerli, T. Soysal, B. Ferhanoglu, et al., The SOCS-1
gene methylation in chronic myeloid leukemia patients, Am. J. Hematol. 82
(2007) 729–730.
[227] G. Guo, Q. Kang, X. Zhu, Q. Chen, X. Wang, Y. Chen, et al., A long noncoding RNA
critically regulates Bcr-Abl-mediated cellular transformation by acting as a com-
petitive endogenous RNA, Oncogene 34 (2015) 1768–1779.
[228] K. Sen, A. Sarkar, R.K. Maji, Z. Ghosh, S. Gupta, T.C. Ghosh, Deciphering the cross-
talking of human competitive endogenous RNAs in K562 chronic myelogenous
leukemia cell line, Mol. Biosyst. 12 (2016) 3633–3642.
[229] D.Q. Feng, B. Huang, J. Li, J. Liu, X.M. Chen, Y.M. Xu, et al., Selective miRNA
expression profile in chronic myeloid leukemia K562 cell-derived exosomes, Asian
Pac. J. Cancer Prev. 14 (2013) 7501–7508.
[230] H. Tadokoro, T. Umezu, K. Ohyashiki, T. Hirano, J.H. Ohyashiki, Exosomes de-
rived from hypoxic leukemia cells enhance tube formation in endothelial cells, J.
Biol. Chem. 288 (2013) 34343–34351.
[231] T. Umezu, K. Ohyashiki, M. Kuroda, J.H. Ohyashiki, Leukemia cell to endothelial
cell communication via exosomal miRNAs, Oncogene 32 (2013) 2747–2755.
[232] R.A. Silveira, A.A. Fachel, Y.B. Moreira, C.A. De Souza, F.F. Costa, S. Verjovski-
Almeida, et al., Protein-coding genes and long noncoding RNAs are differentially
expressed in dasatinib-treated chronic myeloid leukemia patients with resistance
to imatinib, Hematology 19 (2014) 31–41.
[233] E. Farhadi, F. Zaker, M. Safa, M.R. Rezvani, miR-101 sensitizes K562 cell line to
imatinib through Jak2 downregulation and inhibition of NF-kappaB target genes,
Tumour Biol. 37 (2016) 14117–14128.
[234] S. Suresh, L. McCallum, W.H. Lu, N. Lazar, B. Perbal, A.E. Irvine, MicroRNAs
130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML,
J. Cell Commun. Signal. 5 (2011) 183–191.
[235] L. Liu, S. Wang, R. Chen, Y. Wu, B. Zhang, S. Huang, et al., Myc induced miR-144/
451 contributes to the acquired imatinib resistance in chronic myelogenous leu-
kemia cell K562, Biochem. Biophys. Res. Commun. 425 (2012) 368–373.
[236] J.H. Ohyashiki, K. Ohtsuki, I. Mizoguchi, T. Yoshimoto, S. Katagiri, T. Umezu,
et al., Downregulated microRNA-148b in circulating PBMCs in chronic myeloid
leukemia patients with undetectable minimal residual disease: a possible bio-
marker to discontinue imatinib safely, Drug Des. Devel. Ther. 8 (2014)
1151–1159.
[237] O.H. Rokah, G. Granot, A. Ovcharenko, S. Modai, M. Pasmanik-Chor, A. Toren,
et al., Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid
leukemia cells, PLoS One 7 (2012) e35501.
[238] E.I. Zimmerman, C.M. Dollins, M. Crawford, S. Grant, S.P. Nana-Sinkam,
K.L. Richards, et al., Lyn kinase-dependent regulation of miR181 and myeloid cell
leukemia-1 expression: implications for drug resistance in myelogenous leukemia,
Mol. Pharmacol. 78 (2010) 811–817.
[239] J. Fei, Y. Li, X. Zhu, X. Luo, miR-181a post-transcriptionally downregulates on-
cogenic RalA and contributes to growth inhibition and apoptosis in chronic
myelogenous leukemia (CML), PLoS One 7 (2012) e32834.
[240] W. Ma, J. Liu, J. Xie, X. Zhang, H. Zhou, H. Yao, et al., Modulating the growth and
imatinib sensitivity of chronic myeloid leukemia stem/progenitor cells with
Pllulan/microRNA nanoparticles in vitro, J. Biomed. Nanotechnol. 11 (2015)
1961–1974.
[241] N. Mosakhani, S. Mustjoki, S. Knuutila, Down-regulation of miR-181c in imatinib-
resistant chronic myeloid leukemia, Mol Cytogenet 6 (2013).
[242] Y. Liu, W. Zheng, Y. Song, W. Ma, H. Yin, Low expression of miR-196b enhances
the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leuke-
mogenesis, PLoS One 8 (2013) e68442.
[243] F. Albano, L. Anelli, A. Zagaria, V. Liso, M. Rocchi, G. Specchia, MIRN199B
downregulation in chronic myeloid leukaemia is associated with deletions on der
S. Koschmieder, D. Vetrie Seminars in Cancer Biology 51 (2018) 180–197
196
(9), Br. J. Haematol. 144 (2009) 271–273.
[244] A. Chaubey, S. Karanti, D. Rai, T. Oh, S.G. Adhvaryu, R.C. Aguiar, MicroRNAs and
deletion of the derivative chromosome 9 in chronic myeloid leukemia, Leukemia
23 (2009) 186–188.
[245] D. Joshi, S. Chandrakala, S. Korgaonkar, K. Ghosh, B.R. Vundinti, Down-regulation
of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL
positive CML patients, Gene 542 (2014) 109–112.
[246] M.J. Bueno, I. Perez de Castro, M.G. de Cedron, J. Santos, G.A. Calin,
J.C. Cigudosa, et al., Genetic and epigenetic silencing of microRNA-203 enhances
ABL1 and BCR-ABL1 oncogene expression, Cancer Cell 13 (2008) 496–506.
[247] T. Shibuta, E. Honda, H. Shiotsu, Y. Tanaka, S. Vellasamy, M. Shiratsuchi, et al.,
Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of
anti-tumor effect of imatinib, Leuk. Res. 37 (2013) 1278–1286.
[248] Y. Li, Y. Yuan, K. Tao, X. Wang, Q. Xiao, Z. Huang, et al., Inhibition of BCR/ABL
protein expression by miR-203 sensitizes for imatinib mesylate, PLoS One 8 (2013)
e61858.
[249] M. Zhou, J. Zeng, X. Wang, X. Wang, T. Huang, Y. Fu, et al., Histone demethylase
RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia, Oncotarget 6
(2015) 1249–1261.
[250] J. Gu, X. Zhu, Y. Li, D. Dong, J. Yao, C. Lin, et al., miRNA-21 regulates arsenic-
induced anti-leukemia activity in myelogenous cell lines, Med. Oncol. 28 (2011)
211–218.
[251] H. Seca, R.T. Lima, V. Lopes-Rodrigues, J.E. Guimaraes, G.M. Almeida,
M.H. Vasconcelos, Targeting miR-21 induces autophagy and chemosensitivity of
leukemia cells, Curr. Drug Targets 14 (2013) 1135–1143.
[252] E. Turrini, S. Haenisch, S. Laechelt, T. Diewock, O. Bruhn, I. Cascorbi, MicroRNA
profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-
328 on ABCG2 expression, Pharmacogenet. Genomics 22 (2012) 198–205.
[253] K. Ohyashiki, T. Umezu, S. Katagiri, C. Kobayashi, K. Azuma, T. Tauchi, et al.,
Downregulation of plasma miR-215 in chronic myeloid leukemia patients with
successful discontinuation of imatinib, Int. J. Mol. Sci. 17 (2016) 570.
[254] C. Nishioka, T. Ikezoe, J. Yang, A. Nobumoto, M. Tsuda, A. Yokoyama,
Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to
ABL tyrosine kinase inhibitors, Cancer Sci. 105 (2014) 297–307.
[255] Z. Xishan, L. Xianjun, L. Ziying, C. Guangxin, L. Gang, The malignancy suppression
role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia,
Cancer Gene Ther. 21 (2014) 397–404.
[256] T.Y. Lee, H.J. Ezelle, T. Venkataraman, R.G. Lapidus, K.A. Scheibner, B.A. Hassel,
Regulation of human RNase-L by the miR-29 family reveals a novel oncogenic role
in chronic myelogenous leukemia, J. Interferon Cytokine Res. 33 (2013) 34–42.
[257] Y. Yu, L. Yang, M. Zhao, S. Zhu, R. Kang, P. Vernon, et al., Targeting microRNA-
30a-mediated autophagy enhances imatinib activity against human chronic
myeloid leukemia cells, Leukemia 26 (2012) 1752–1760.
[258] Y. Liu, Y. Song, W. Ma, W. Zheng, H. Yin, Decreased microRNA-30a levels are
associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid
leukemia, Leuk. Res. 37 (2013) 349–356.
[259] O. Hershkovitz-Rokah, S. Modai, M. Pasmanik-Chor, A. Toren, N. Shomron,
P. Raanani, et al., MiR-30e induces apoptosis and sensitizes K562 cells to imatinib
treatment via regulation of the BCR-ABL protein, Cancer Lett. 356 (2015)
597–605.
[260] Z. Xishan, L. Ziying, D. Jing, L. Gang, MicroRNA-320a acts as a tumor suppressor
by targeting BCR/ABL oncogene in chronic myeloid leukemia, Sci. Rep. 5 (2015)
12460.
[261] S. Babashah, M. Sadeghizadeh, A. Hajifathali, M.R. Tavirani, M.S. Zomorod,
M. Ghadiani, et al., Targeting of the signal transducer Smo links microRNA-326 to
the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells, Int. J.
Cancer 133 (2013) 579–589.
[262] A.M. Eiring, J.G. Harb, P. Neviani, C. Garton, J.J. Oaks, R. Spizzo, et al., MiR-328
functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation
in leukemic blasts, Cell 140 (2010) 652–665.
[263] Y. Yang, L. Ding, Z.K. Guo, X.L. Zheng, L.S. Wang, H.Y. Sun, et al., The epigen-
etically-regulated miR-34a targeting c-SRC suppresses RAF/MEK/ERK signaling
pathway in K-562 cells, Leuk. Res. 55 (2017) 91–96.
[264] P. Yang, F. Ni, R.Q. Deng, G. Qiang, H. Zhao, M.Z. Yang, et al., MiR-362-5p pro-
motes the malignancy of chronic myelocytic leukaemia via down-regulation of
GADD45alpha, Mol. Cancer 14 (2015) 190.
[265] M. Zhou, J. Zeng, X. Wang, Q. Guo, T. Huang, H. Shen, et al., MiR-370 sensitizes
chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead
box M1, J. Transl. Med. 11 (2013) 265.
[266] K. Hussein, G. Busche, M. Muth, G. Gohring, H. Kreipe, O. Bock, Expression of
myelopoiesis-associated microRNA in bone marrow cells of atypical chronic
myeloid leukaemia and chronic myelomonocytic leukaemia, Ann. Hematol. 90
(2011) 307–313.
[267] O. Hershkovitz-Rokah, S. Modai, M. Pasmanik-Chor, A. Toren, N. Shomron,
P. Raanani, et al., Restoration of miR-424 suppresses BCR-ABL activity and sen-
sitizes CML cells to imatinib treatment, Cancer Lett. 360 (2015) 245–256.
[268] L.S. Wang, L. Li, L. Li, S. Chu, K.D. Shiang, M. Li, et al., MicroRNA-486 regulates
normal erythropoiesis and enhances growth and modulates drug response in CML
progenitors, Blood 125 (2015) 1302–1313.
[269] S. Bhutra, D. Lenkala, B. LaCroix, M. Ye, R.S. Huang, Identifying validating a
combined mRNA and microRNA signature in response to imatinib treatment in a
chronic myeloid leukemia cell line, PLoS One 9 (2014) e115003.
[270] B.T. Kaymaz, V.B. Cetintas, C. Aktan, B. Kosova, MicroRNA-520a-5p displays a
therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3
and enhances the anticarcinogenic role of capsaicin, Tumour Biol. 35 (2014)
8733–8742.
[271] F.C. de Faria, M.E. Leal, P.S. Bernardo, P.R. Costa, R.C. Maia, NFkappaB pathway
and microRNA-9 and −21 are involved in sensitivity to the pterocarpanquinone
LQB-118 in different CML cell lines, Anticancer Agents Med. Chem. 15 (2015)
345–352.
[272] K. Wang, Z. Xu, N. Wang, Y. Tian, X. Sun, Y. Ma, Analysis of microRNA and gene
networks in human chronic myelogenous leukemia, Mol. Med. Rep. 13 (2016)
453–460.
S. Koschmieder, D. Vetrie Seminars in Cancer Biology 51 (2018) 180–197
197
